<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 201905//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8512414</article-id><article-id pub-id-type="doi">10.3390/molecules26196057</article-id><article-id pub-id-type="publisher-id">molecules-26-06057</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan, Sulfonamides, and &#x003b2;-Lactams</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5773-6874</contrib-id><name><surname>Christensen</surname><given-names>S&#x000f8;ren Br&#x000f8;gger</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Sim&#x000f5;es</surname><given-names>Manuel</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-26-06057">The Museum of Natural Medicine &#x00026; The Pharmacognostic Collection, University of Copenhagen, Jagtvej 162, DK-2100 Copenhagen, Denmark; <email>soren.christensen@sund.ku.dk</email>; Tel.: +45-3533-6253</aff><pub-date pub-type="epub"><day>07</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2021</year></pub-date><volume>26</volume><issue>19</issue><elocation-id>6057</elocation-id><history><date date-type="received"><day>15</day><month>8</month><year>2021</year></date><date date-type="accepted"><day>29</day><month>9</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the author.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The appearance of antibiotic drugs revolutionized the possibilities for treatment of diseases with high mortality such as pneumonia, sepsis, plaque, diphtheria, tetanus, typhoid fever, and tuberculosis. Today fewer than 1% of mortalities in high income countries are caused by diseases caused by bacteria. However, it should be recalled that the antibiotics were introduced in parallel with sanitation including sewerage, piped drinking water, high standard of living and improved understanding of the connection between food and health. Development of salvarsan, sulfonamides, and &#x003b2;-lactams into efficient drugs is described. The effects on life expectancy and life quality of these new drugs are indicated.</p></abstract><kwd-group><kwd>bacterial infectious diseases</kwd><kwd>salvarsan</kwd><kwd>sulfonamides</kwd><kwd>penicillins</kwd><kwd>cephalosporins</kwd><kwd>carbapenems</kwd><kwd>thiopenems</kwd><kwd>monobactams</kwd><kwd>&#x003b2;-lactamases</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-26-06057"><title>1. Introduction</title><p>Infectious or communicative diseases have been a severe burden for mankind for millennia. The absence of knowledge of the pathogen organisms prevented prophylaxis and treatment of the maladies until the early 21st century. In Denmark, an overview of morbidity reveals that in the period 1876&#x02013;1880 communicative diseases were the cause of almost 3/4 (72%) of mortality, in the period 1900&#x02013;1903 almost half the deaths (42%), in 1920 about a 1/7 (15%), in 1945 only 4% and in 2013 only 0.5% [<xref rid="B1-molecules-26-06057" ref-type="bibr">1</xref>,<xref rid="B2-molecules-26-06057" ref-type="bibr">2</xref>]. The abrupt fall in death rate of communicative infections was caused by sanitation, higher living standards and introduction of efficient drugs as will be explained below. Bacteria were described as animalcules already in 1683 by the Dutch merchant Leeuwenhoeck [<xref rid="B3-molecules-26-06057" ref-type="bibr">3</xref>,<xref rid="B4-molecules-26-06057" ref-type="bibr">4</xref>]; but the importance of the discovery was not realized until 200 years later. Several different microorganisms were described and depictured by a Danish scientist M&#x000fc;ller in the atlas <italic toggle="yes">Animalcula infusoria fluviatilia et marina</italic> (1786) [<xref rid="B5-molecules-26-06057" ref-type="bibr">5</xref>]. The first correlation between microorganisms and health came in 1836 when the Italian civil servant Bassi described that a minute fungus (<italic toggle="yes">Botrytis bassina</italic>) was fatal to silkworms. The German clinician Sh&#x000f6;nlein realized in 1839 that the pathogen causing the human skin disease favus was a fungus (<italic toggle="yes">Achorion sch&#x000f6;leinii</italic>). Some scientists proposed in the 1830s that fermentation was a conversion of organic compound performed by living microorganisms (yeast). However, leading chemists such as Berzelius and Liebig suggested that fermentation was a purely chemical process [<xref rid="B3-molecules-26-06057" ref-type="bibr">3</xref>]. In 1873, Pasteur published a study on the diseases of the vine revealing that in the microscope he could see two organisms on the surface of the peel of grapes, some small organisms and some big organisms. By heating the grapes to 80 &#x02103; the small organisms were killed but the big survived. This later has been called Pasteurization [<xref rid="B6-molecules-26-06057" ref-type="bibr">6</xref>]. Today the small organisms are known as bacteria and the big organisms as yeast. Another important contribution of Pasteur was the demonstration that life does not evolve spontaneously. Development of life in uninfected media was demonstrated to originate from germs present in the air. In 1849, Davaine demonstrated the presence of <italic toggle="yes">Bacillus anthracis</italic> in the blood of cattle suffering from anthrax. This was the first mammalian disease for which a bacterium was shown to be the pathogenic organism. Pasteur showed in 1877 that transfer of blood from an infected animal to a healthy animal communicates the disease. Pasteur also realized that virulence of the anthrax bacteria could be attenuated by cultivation at high temperature. Inoculation in animals with the attenuated organism protected the animal from developing disease. The technique of decreased virulence was used for prevention of rabies in a boy bitten by a mad dog. In 1882 Koch discovered the tubercle bacterium (<italic toggle="yes">Mycobacterium tuberculosis</italic>). The studies of Pasteur and Koch formed the foundation of bacteriology as we know it today [<xref rid="B3-molecules-26-06057" ref-type="bibr">3</xref>]. After these pioneering studies several pathogenic bacteria were characterized, <italic toggle="yes">Corynebacterium diphteriae</italic> (diphtheria) <italic toggle="yes">Pasteurella pestris</italic> (plague), <italic toggle="yes">Clostridium tetani</italic> (tetanus), <italic toggle="yes">Salmonella typhosa</italic> (typhoid fever), and <italic toggle="yes">Mycobacterium tuberculosis</italic> (tuberculosis). In 1900, pathogenic organisms causing 21 diseases were discovered [<xref rid="B3-molecules-26-06057" ref-type="bibr">3</xref>]. A late discovery of new pathogenic agents was made in 1983 when bacteria were discovered in the stomach of patients suffering from gastritis and peptic ulceration [<xref rid="B7-molecules-26-06057" ref-type="bibr">7</xref>,<xref rid="B8-molecules-26-06057" ref-type="bibr">8</xref>]. The bacteria later were identified as <italic toggle="yes">Campylobacter pyloridis</italic> [<xref rid="B9-molecules-26-06057" ref-type="bibr">9</xref>]. The discovery was met with some skepticism, since it was difficult to accept that bacteria could live in the hostile environment of the stomach [<xref rid="B10-molecules-26-06057" ref-type="bibr">10</xref>]. In 2008, Warren and Marshall were awarded the Nobel Price for their discovery of the pathogenic properties of what today is known as <italic toggle="yes">Helicobacter pylori</italic> [<xref rid="B10-molecules-26-06057" ref-type="bibr">10</xref>]. In 2001, several 1425 infectious organisms were known, including 217 virus and prions, 538 bacteria, 307 fungi, 66 protozoa, and 287 helminths [<xref rid="B11-molecules-26-06057" ref-type="bibr">11</xref>].</p><p>The importance of hygiene for life expectancy was gradually understood in the last part of the 19th century. The ideal man in Greek/Roman philosophy was healthy and beautiful. To obtain a beautiful body, public baths were needed. Aquaducts provided fresh and clean water and public latrines were used. Sewers (cloacae) build in the 6th century B.C. are still a part of the Roman sewerage. According to Christianity, the body is just the holster for the soul and consequently needed no attention [<xref rid="B12-molecules-26-06057" ref-type="bibr">12</xref>]. After the fall of the Roman Empire in the 5th century A.D., hygiene in Europe declined. In contrast, it was to some extent maintained in Medieval Muslim Europe [<xref rid="B13-molecules-26-06057" ref-type="bibr">13</xref>]. Urbanization as a consequence of industrialization afforded metropoles with poor hygiene. Two major cholera outbreaks (1848&#x02013;1849 and 1865&#x02013;1867) encouraged sanitation. Construction of sewerages in most major European cities were completed in the last decade of the 19th century [<xref rid="B13-molecules-26-06057" ref-type="bibr">13</xref>]. It soon was realized that dumping of the superfluous water and filth in rivers or seas caused unacceptable contamination. Consequently biological filters were installed in the early 21st century [<xref rid="B13-molecules-26-06057" ref-type="bibr">13</xref>]. Sanitation was a time consuming project, even in the 1970s apartments with shared latrines in the backyard with no drainage could still be found in Copenhagen and probably also in other European cities. It is encouraging to realize that the construction of sewerage was initiated after the big cholera epidemics, but before it was established that the cholera bacteria (<italic toggle="yes">Vibrio cholerae</italic>) was the pathogenic organism 1883 [<xref rid="B3-molecules-26-06057" ref-type="bibr">3</xref>]. Supply of clean piped water in general developed slower since this very often was constructed by private enterprises [<xref rid="B13-molecules-26-06057" ref-type="bibr">13</xref>,<xref rid="B14-molecules-26-06057" ref-type="bibr">14</xref>]. In northern Europe most cities had piped water in 1915 and most cities in southern Europe in 1940. Later the importance of higher standards of living and proper food has been realized [<xref rid="B3-molecules-26-06057" ref-type="bibr">3</xref>].</p><p>The effect of sanitation is clearly revealed by the abrupt fall in mortality caused by infectious diseases in the period 1875 to 1920. However, one infectious disease remained unaffected: syphilis [<xref rid="B1-molecules-26-06057" ref-type="bibr">1</xref>]. Efficient therapy for bacterial diseases slowly started to appear in the second decade of the 20th century but the breakthrough came when sustainable production of penicillin was invented in the 1940s. The naturally occurring &#x003b2;-lactams afforded access to efficient antibiotic drugs [<xref rid="B15-molecules-26-06057" ref-type="bibr">15</xref>,<xref rid="B16-molecules-26-06057" ref-type="bibr">16</xref>,<xref rid="B17-molecules-26-06057" ref-type="bibr">17</xref>]. The term chemotherapy was introduced by Ehrlich. It was defined as the use of drugs to injure an invading organism without injure to the host [<xref rid="B18-molecules-26-06057" ref-type="bibr">18</xref>]. Later antibiotics were defined as compounds combating invading organisms [<xref rid="B19-molecules-26-06057" ref-type="bibr">19</xref>]. Today the term chemotherapeutics is mainly used for drugs curing cancer diseases, in contrast to the original definition of Ehrlich. Antibiotics are drugs curing infectious diseases, irrespectively of natural or synthetic origin. The years from about 1940 to 1960 were the golden age of antibiotics. In this period most of the antibiotic classes used today were introduced. Emerging resistance toward antibiotics, however, becomes an increasing threat. In 2012, the Congress of the USA passed legislation for antibiotic development. In 2014, president Obama issued an order for substantial government intervention to stimulate infectious disease research and drug development [<xref rid="B20-molecules-26-06057" ref-type="bibr">20</xref>]. Not all bacteria are hostile. An intact intestinal microbiota affords and important protection against pathogenic bacteria. Antibiotics should be used with care to prevent corruption of the intestinal flora [<xref rid="B21-molecules-26-06057" ref-type="bibr">21</xref>]. The difference between antibiotics and vaccination (<xref rid="sec9-molecules-26-06057" ref-type="sec">Section 9</xref>) is that the former only cure a disease, whereas the latter primarily prevents infection.</p></sec><sec id="sec2-molecules-26-06057"><title>2. Arsphenamine (Salvarsan)</title><p>The number of deaths of communicative diseases dramatically decreased in the period from 1875 to 1903. In contrast, the morbidity of syphilis remained approximately 0.2% of all deaths in Denmark [<xref rid="B1-molecules-26-06057" ref-type="bibr">1</xref>]. Syphilis, &#x0201c;the terror of the early 20th century [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>]&#x0201d;, was a heavy burden in other parts of Europe, with 1/6 of all Parisians and 1/10 of all Londoners infected [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>]. The first efficient drug was based on a wrong but fruitful working hypothesis made by Paul Ehrlich: &#x0201c;Some dyes specifically color some organs and microorganisms. Consequently, these dyes can be used for selective targeting these organs or organisms.&#x0201d; Based on this observation Ehrlich concluded that a magic bullet (<italic toggle="yes">die magische Kugel</italic>) can be designed. The magic bullet enables selective killing of microorganisms or cancer cells. Ehrlich tested several compounds for their ability to cure syphilis infected mice. In 1909, compound 606, arsphenamine or salvarsan (<xref rid="molecules-26-06057-f001" ref-type="fig">Figure 1</xref>) turned out to have an effect. Already a year later positive clinical results were published [<xref rid="B23-molecules-26-06057" ref-type="bibr">23</xref>]. The synthetic path for preparation of arsphenamine occasionally resulted in toxic contaminants [<xref rid="B24-molecules-26-06057" ref-type="bibr">24</xref>]. Thus, after only a few decades the drug was displaced with the safer penicillin [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>]. In most databases and textbooks arsphenamine is depicted as <bold>1a</bold> (<xref rid="molecules-26-06057-f001" ref-type="fig">Figure 1</xref>). However, ESI MS has revealed that the molecule is a mixture of cyclic compounds <bold>1b</bold>, with different numbers of arsenic atoms in the ring. The dominating molecules are trimers of 4-hydroxy-3-aminophenylarsen (<bold>1b</bold>, n = 1) and pentamers (n = 3), but also tetramers, hexamers and heptamers (n equals 2, 4 and 5) are present [<xref rid="B24-molecules-26-06057" ref-type="bibr">24</xref>]. Arsphenamine was marketed as salvarsan. Poor aqueous solubility of arsphenamin was overcome by preparation of neosalvarsan, for which the structure <bold>2a</bold> has been suggested [<xref rid="B18-molecules-26-06057" ref-type="bibr">18</xref>]. Later studies suggested that the cyclic arsenicals only are prodrugs of the active warhead osphenarsine <bold>3</bold> [<xref rid="B24-molecules-26-06057" ref-type="bibr">24</xref>]. Arsphenamine was the first marketed antibiotic, which cured an infectious disease caused by bacteria [<xref rid="B25-molecules-26-06057" ref-type="bibr">25</xref>]. For a period until the 1940s, oxphenarsine (<bold>3</bold>) replaced salvarsan under the tradename Mapharsen until only penicillin was used for treatment of syphilis [<xref rid="B18-molecules-26-06057" ref-type="bibr">18</xref>].</p><p>Arspehnamine was not the first example of a magic bullet, quinine used for the treatment of malaria had been known for almost a century [<xref rid="B26-molecules-26-06057" ref-type="bibr">26</xref>]. </p></sec><sec id="sec3-molecules-26-06057"><title>3. Sulfonamides</title><sec id="sec3dot1-molecules-26-06057"><title>3.1. Discovery</title><p>Ehrlich&#x02019;s idea of a magic bullet inspired G. Domagk to test several hundred compounds. Azo compounds gave promising results when tested on mice infected with streptococci, but were inactive in vitro [<xref rid="B27-molecules-26-06057" ref-type="bibr">27</xref>]. On December 20, 1932 prontosil (<xref rid="molecules-26-06057-f002" ref-type="fig">Figure 2</xref>, <bold>4</bold>) was shown to prevent mice and rabbits from dying of a lethal infection of <italic toggle="yes">Streptococcus</italic> [<xref rid="B28-molecules-26-06057" ref-type="bibr">28</xref>]. Soon after filing of the patent clinical studies were performed. Patients suffering from infections with <italic toggle="yes">Streptococcus</italic> were treated. Encouraging positive results were obtained in most cases, although severe infections did not respond satisfactory [<xref rid="B29-molecules-26-06057" ref-type="bibr">29</xref>,<xref rid="B30-molecules-26-06057" ref-type="bibr">30</xref>]. Domagk&#x02019;s daughter at six years of age developed a life threatening infection, which in a miraculous way was cured by administration of prontosil [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>]. The compound developed into a blockbuster for I. G. Farben, at which Domagk was employed. In 1935 the sale of Prontosil totaled 175,000 marks, 1936 the sale rose to about 1 million marks and in 1937 more than 5 million marks [<xref rid="B27-molecules-26-06057" ref-type="bibr">27</xref>]. Soon the drug was introduced to the world. It was considered a &#x0201c;miracle drug&#x0201d;. Since German patents were not recognized in France, an independent production was made in this country under the name of rubiazol. A side effect was that the skin of some patients became reddish. Fortunately this effect was temporary. The introduction of the sulfa drugs was a turning point in treatment of streptococcal diseases such as childbed fever and septicemia, pneumonia, meningitis, dysentery, gonorrhea, and urinary tract infections [<xref rid="B27-molecules-26-06057" ref-type="bibr">27</xref>]. Already in 1939, Domagk was offered the Nobel Price, but the situation in Germany prevented him from receiving it until 1947 [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>].</p><p>By accident Bovet&#x02019;s group in 1935 tested 4-aminobenzenesulfamide (sulfanilamide, <bold>5</bold>) for treatment of streptococcal infections in rabbits. To their surprise and disappointment <bold>5</bold> was as efficient as prontosil. However, some reflections led to the conclusion that the discovery of a simple but efficient molecule opened the possibilities for designing new simple antibiotics [<xref rid="B31-molecules-26-06057" ref-type="bibr">31</xref>]. Shortly thereafter a new study revealed that in contrast to prontosil 4-aminobezenesulfonamide inhibits the growth of bacteria in vitro and is efficient for treatment of streptococcal infections in man [<xref rid="B32-molecules-26-06057" ref-type="bibr">32</xref>]. It is now accepted that prontosil (<bold>4</bold>) is a prodrug for 4-aminobenzenesulfonamide (<bold>5</bold>) formed by reductive cleavage of the N=N double bond [<xref rid="B33-molecules-26-06057" ref-type="bibr">33</xref>]. </p><p>In 1938, May and Baker marketed 4-sulfapyridine (<bold>6</bold>) as the first sulfa drug, which could cure &#x0201c;captain of the death&#x0201c; bacterial pneumonia. In late 1943 Winston Churchill suffered from a potentially lethal pneumonia. The infection was miraculously cured by 4-sulfapyridine (<bold>6</bold>), a sale promoting event [<xref rid="B27-molecules-26-06057" ref-type="bibr">27</xref>]. The introduction of sulfa drugs for treatment of infections revolutionized treatment of streptococcal infections in the early 20th century [<xref rid="B34-molecules-26-06057" ref-type="bibr">34</xref>]. The introduction of penicillin decreased the demand for sulfa drugs [<xref rid="B27-molecules-26-06057" ref-type="bibr">27</xref>]. </p></sec><sec id="sec3dot2-molecules-26-06057"><title>3.2. Mechanism of Action</title><p>If bacteria are incubated with yeast extract containing 4-aminobenzoate and sulfanilamide (<bold>5</bold>) the growth inhibition is antagonized (<xref rid="molecules-26-06057-sch001" ref-type="fig">Scheme 1</xref>, <bold>8</bold>) [<xref rid="B35-molecules-26-06057" ref-type="bibr">35</xref>]. This discovery led to understanding of the mechanism of action of sulfanilamide. Tetrahydrofolate (<bold>10</bold>) is formed from the building blocks 7,8-dihydropteridinepyrophosphate (<bold>7</bold>) and 4-aminobenzoic acid (<bold>8</bold>) in bacteria [<xref rid="B36-molecules-26-06057" ref-type="bibr">36</xref>]. Sulfonamide (<xref rid="molecules-26-06057-f003" ref-type="fig">Figure 3</xref>, <bold>5</bold>) interacts with dihydropteroate synthase and prevents formation of tetrahydrofolate (<bold>10</bold>). If sufficient 4-aminobenzoate is present sulfonamide will be displayed from the enzyme neutralizing the inhibition. Tetrahydrofolate (<bold>10</bold>), a precursor for folic acid, is a vitamin for mammalian [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>]. Consequently, administration of an antimetabolite of 4-aminobenzoic acid (<bold>8</bold>) does not affect mammalian cells. If no other targets for sulfanilamide than the tetrahydrofolate existed, the compound would be harmless for mammalians, whereas it is a potent proliferation toxin for microorganisms. </p><p>The sulfonamides have two proteolytic groups the sulfonamide with a pK<sub>A</sub> value of 5&#x02013;8 and the protonated amino group pK<sub>A</sub> 2&#x02013;2.5 [<xref rid="B36-molecules-26-06057" ref-type="bibr">36</xref>]. Poor aqueous solubility complicates administration of sulfa drugs. Consequently, they are administered as the more water soluble sodium salts.</p><p>Side effects of sulfonamides or accidentals discoveries have led to several drugs possessing the pharmacophore, but with no antibiotic effects. Examples of such drugs are acetazolamide and furosemide (both used as diuretics), glibenclamide (for treatment of diabetes mellitus 2), parecoxib (a COX2 inhibitor) and dofetilide (a class III antiarrhythmic drug) [<xref rid="B36-molecules-26-06057" ref-type="bibr">36</xref>]. </p></sec></sec><sec id="sec4-molecules-26-06057"><title>4. &#x003b2;-Lactams</title><p>Six ring systems including a &#x003b2;-lactam ring are found in nature &#x003b2;-lactams, penams, cephems, clavan, penems or thiopenem and carbapenems (<xref rid="molecules-26-06057-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>]. The clinical use of &#x003b2;-lactams has revolutionized treatment of infectious diseases [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. The systematic name for the &#x003b2;-lactam ring is azetidinone.</p><sec id="sec4dot1-molecules-26-06057"><title>4.1. Discovery of the Penicillins</title><p>If untreated infections with <italic toggle="yes">Streptococcus aureus</italic> might be fatal. In the first decades of the 20th century, no drug for treatment was known [<xref rid="B39-molecules-26-06057" ref-type="bibr">39</xref>]. By accident, studies of the rare mold <italic toggle="yes">Penicillium rubrum</italic> were performed in laboratories in the vicinity of Flemings laboratory. Some spores appeared on a Petri dish used for growth of <italic toggle="yes">Staphylocccus sp.</italic> This dish was left by Fleming in his laboratory during a holiday. During his absence an unusually cold period in London favored the growth of <italic toggle="yes">p. rubrum</italic>. When the mold culture was well established, the temperature rose favoring growth of <italic toggle="yes">S. aureus.</italic> Inhibition zones around the mold colonies led Fleming to the conclusion that antibacterial compounds were produced, a simple but far reaching conclusion [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>]. The growth of several other bacteria such as <italic toggle="yes">Staphylococcus pyrogenes</italic>, <italic toggle="yes">Streptococcus pyrogenes</italic>, <italic toggle="yes">Streotococcus viridans</italic>, diphteroid bacillus, and <italic toggle="yes">Micrococcus lysodeikticus</italic> was also inhibited, but not the growth of <italic toggle="yes">Bacillus anthracis</italic>, <italic toggle="yes">Bacillus typhoeus</italic>, and enterococcus [<xref rid="B40-molecules-26-06057" ref-type="bibr">40</xref>]. In his publication from 1929, Fleming claimed that <italic toggle="yes">p. rubrum</italic> had contaminated his dishes [<xref rid="B40-molecules-26-06057" ref-type="bibr">40</xref>]. Later publications, however, mention <italic toggle="yes">p. notatum</italic> [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>,<xref rid="B41-molecules-26-06057" ref-type="bibr">41</xref>]. Fleming used the broth of <italic toggle="yes">p. rubrum</italic> to cure a severe conjunctivitis in a student [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>]. These data, surprisingly, did not call for attention. This situation changed when Florey at the University of Oxford took up the challenge to develop a protocol for large scale production of penicillin. Florey supervised a group consisting of two biochemists Chain and Heatley. Industrial large scale production of penicillin, however, first succeeded when Florey and Chain went to the USA. They constructed 500 gallon tanks, replaced the growth medium with corn steep liquor and found a new <italic toggle="yes">Penicillium</italic> species (<italic toggle="yes">p. chrysogenum</italic>) producing 100 times more penicillin. These changes enabled production of penicillin in ton scale. By up scaling the equipment to 7500 gallon tanks Pfizer produced 4 tons in 1945 [<xref rid="B22-molecules-26-06057" ref-type="bibr">22</xref>,<xref rid="B41-molecules-26-06057" ref-type="bibr">41</xref>,<xref rid="B42-molecules-26-06057" ref-type="bibr">42</xref>]. The results from the first clinical trials were so impressive that the US army immediately included penicillin in the armamentarium for combating infections in the military hospitals [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>]. The US army, being the main sponsor, received all the produced penicillin until the production in 1945 fulfilled the army&#x02019;s demand. The surplus enabled civilians to benefit from the drug. F-pencicllin (<xref rid="molecules-26-06057-f005" ref-type="fig">Figure 5</xref>, <bold>22</bold>) and I-dihydropenicilllin (<bold>23</bold>) were the first isolated natural products possessing the penam nucleus. The <italic toggle="yes">N</italic>-acyl side chain originates from carboxylic acids in the medium. The phenylacetyl group in G-penicllin (<bold>24</bold>) was introduced after shifting the medium to corn steep liquor [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. Addition of different carboxylic acids to the medium enables variation of the <italic toggle="yes">N</italic>-acyl group [<xref rid="B42-molecules-26-06057" ref-type="bibr">42</xref>,<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. Even today after development of sophisticated syntheses for azetidinone the majority of pencillins marketed are made by semisyntheses using starting materials obtained from <italic toggle="yes">Penicillium</italic> broths [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>,<xref rid="B45-molecules-26-06057" ref-type="bibr">45</xref>].</p><p>In addition to the impressive research performed in UK and USA a small pharmaceutical company in Denmark, L&#x000f8;vens Kemiske Fabrik (today Leo Pharma), succeeded in production of penicillin already in 1943. The prepared penicillin was used in some clinical cases. The late Danish Minister of Foreign Affairs, Per Stig M&#x000f8;ller, was cured for pneumonia. Production was shut down in 1944 to prevent the Nazi occupation forces from accessing the strategic valuable drug [<xref rid="B46-molecules-26-06057" ref-type="bibr">46</xref>]. After the war, the production was reestablished and the company became an important supplier to the market. </p></sec><sec id="sec4dot2-molecules-26-06057"><title>4.2. Structure Elucidation and Chemistry of Penicillin</title><p>The structure of penicillin was established through several chemical reactions (<xref rid="molecules-26-06057-sch002" ref-type="fig">Scheme 2</xref> and <xref rid="molecules-26-06057-sch003" ref-type="fig">Scheme 3</xref>) and by X-ray crystallography. The structure was published in two almost identical manuscripts in Nature and Science authored by research groups from several Anglo-American pharmaceutical companies. From a historical point of view the two publications are instructive examples on structure elucidation before the development of spectroscopy [<xref rid="B47-molecules-26-06057" ref-type="bibr">47</xref>,<xref rid="B48-molecules-26-06057" ref-type="bibr">48</xref>]. In the 1940s, the challenge of elucidating the structure of a crystalline compound with molecular weight of about 350 required enormous intellectual and financial resources as evidenced by the list of contributors to the two manuscripts [<xref rid="B47-molecules-26-06057" ref-type="bibr">47</xref>,<xref rid="B48-molecules-26-06057" ref-type="bibr">48</xref>,<xref rid="B49-molecules-26-06057" ref-type="bibr">49</xref>]. Hodgkin published an X-ray analysis of a crystalline sodium salt of <bold>22</bold> confirming the previously reported results [<xref rid="B50-molecules-26-06057" ref-type="bibr">50</xref>]. Several misleading structures were suggested before the correct structure was established [<xref rid="B49-molecules-26-06057" ref-type="bibr">49</xref>]. Today, an average master&#x02019;s student might elucidate the structure in weeks, taking advantage of developed spectroscopy tools. The 2D NMR pulse sequences developed by the recently deceased Nobel laureate Richard R. Ernst in particular has facilitated structure elucidation [<xref rid="B49-molecules-26-06057" ref-type="bibr">49</xref>].</p><p>Tension in the &#x003b2;-lactam ring causes the lactam to be extremely reactive compared to other amides. The stability of amides is partly explained by the two resonance structures the amide and the zwitterionic structure. Tension in the four-membered lactam ring makes the zwitterionic resonance structure unfavorable (<xref rid="molecules-26-06057-sch004" ref-type="fig">Scheme 4</xref>) [<xref rid="B45-molecules-26-06057" ref-type="bibr">45</xref>,<xref rid="B51-molecules-26-06057" ref-type="bibr">51</xref>]. As a consequence, penicillin reacts freely with alcohols. In penicillin-binding peptides a serine residue in the active site is esterified by the penicillins [<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>]. Other examples of reactive cyclic amides are known (see <xref rid="sec9-molecules-26-06057" ref-type="sec">Section 9</xref>) [<xref rid="B53-molecules-26-06057" ref-type="bibr">53</xref>].</p><p>From a biogenetic point of view penicillin is a non-ribosomal peptide originating in the peptide &#x003b6;-L-aminoadipidoyl-L-cysteinoyl-D-isovalerine, which by the enzymes isopenicillin <italic toggle="yes">N</italic>-synthase and isopenicillin N <italic toggle="yes">N</italic>-acyltransferase is converted into penicillin G (<xref rid="molecules-26-06057-sch005" ref-type="fig">Scheme 5</xref>, <bold>24</bold>) [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>,<xref rid="B54-molecules-26-06057" ref-type="bibr">54</xref>]</p><p>A major step in developing later generations of penicillins was discovery of 6-aminopenicillanic acid in a broth used for production of the penicillins <bold>22</bold>&#x02013;<bold>26</bold> (<xref rid="molecules-26-06057-f006" ref-type="fig">Figure 6</xref>, <bold>38</bold>). Despite the level of molecules possessing the &#x003b2;-lactam ring the broth revealed an unexpected low antibiotic effect. This discrepancy was solved by the poor antibiotic effect of isolated <bold>38</bold> [<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>]. Access to the free amine facilitated syntheses of several penicillin analogues enabling development of later generations of penicillins [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B42-molecules-26-06057" ref-type="bibr">42</xref>,<xref rid="B56-molecules-26-06057" ref-type="bibr">56</xref>,<xref rid="B57-molecules-26-06057" ref-type="bibr">57</xref>].</p></sec><sec id="sec4dot3-molecules-26-06057"><title>4.3. Mechanism of Action of Penicillins</title><p>The cell wall or cell envelope is and essential polymer surrounding and enclosing bacteria, Defects in the polymer might be lethal [<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>]. Several enzymes and transporters are involved in the construction of the cell wall including several penicillin-binding peptides (PBP). The cell wall of <italic toggle="yes">Staphylococcus aureus</italic> is fortified by crosslinking strands of peptidoglycans with strands of peptides as illustrated by the cartoon shown in <xref rid="molecules-26-06057-f007" ref-type="fig">Figure 7</xref> [<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>,<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>]. The L-lysine residue is replaced with meso-diaminopimelic acid in other bacteria [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. </p><p>The cross binding occurs by elimination of the terminal D-alanine in one peptidoglycan strand by an attack of the amino bond of a glycine residue terminating a side chain in another peptidoglycan strand (<xref rid="molecules-26-06057-f008" ref-type="fig">Figure 8</xref>) [<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>]. Hereby a cross linking of the two peptidoglycan strands is obtained. This mechanism deviates from pervious described mechanism for cross binding [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. </p><p>The penicillin nucleus is isoster to the terminal D-Ala-D-Ala unit essential in the cross binding process (the Tipper-Strominger hypothesis) [<xref rid="B59-molecules-26-06057" ref-type="bibr">59</xref>]. By interacting with and acylating the serine hydroxyl group in the penicillin-binding transpeptidases [<xref rid="B60-molecules-26-06057" ref-type="bibr">60</xref>] cross binding and consequently formation of a stable cell wall in the bacteria is prevented [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>,<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>]. It was hypothesized that the 6&#x003b1;-methyl analog of penicillin was a closer analog to the D-Ala-D-Ala target. Surprisingly, the compound showed much poorer activity [<xref rid="B61-molecules-26-06057" ref-type="bibr">61</xref>].</p><p>Gram-positive and Gram-negative bacteria differ in Gram-staining. Gram-negative bacteria possess an outer cell membrane, which prevents some antibiotics from reaching their target molecules. The outer membrane possess protein channels (porins) allowing small molecules such as nutrients or antibiotics to penetrate down a concentration gradient to reach the inner parts of the bacteria [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>].</p></sec><sec id="sec4dot4-molecules-26-06057"><title>4.4. Late Generations Penicillins</title><p>The first isolated penicillins were characterized by simple acyl groups at <italic toggle="yes">N</italic>-6 (<xref rid="molecules-26-06057-f005" ref-type="fig">Figure 5</xref>). All of these have the drawback that they to a large extent are degraded in the acidic medium in the stomach. In addition they only show activity against a narrow spectrum of bacteria. Access to 6-aminopenicillanic acid (<bold>38</bold>) facilitated synthesis of analogues with different acyl groups. Today <bold>38</bold> is prepared by enzymatic cleavage of penicillin G (<bold>24</bold>) [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>,<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>]. Compound <bold>38</bold> had previous been mentioned but the potential was never realized by the Japanese scientists [<xref rid="B62-molecules-26-06057" ref-type="bibr">62</xref>]. Early successes with semisynthetic penicillins were obtained by preparing amides of phenoxyacetic acids (<bold>39</bold>&#x02013;<bold>41</bold>) [<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>]. The compounds are also named phenoxyalkyl penicillins. The compounds <bold>40</bold> and <bold>41</bold> are administered as racemic mixtures. The phenoxyacetamides are more acid resistant and are adsorbed about four times more efficient from the stomach [<xref rid="B63-molecules-26-06057" ref-type="bibr">63</xref>,<xref rid="B64-molecules-26-06057" ref-type="bibr">64</xref>]. The presence of an oxygen atom &#x003b2; to the carbonyl group makes the side chain carbonyl much less electrophilic and prevented reaction with the lactam carbonyl in acidic media [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B42-molecules-26-06057" ref-type="bibr">42</xref>]. The compounds were developed in the late 1950s [<xref rid="B42-molecules-26-06057" ref-type="bibr">42</xref>,<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>]. Phenoxymethyl penicillin (<bold>39</bold>&#x02013;<bold>41</bold>) and penicillin G (<bold>24</bold>) are used orally for treatment of strains of Gram-positive cocci [<xref rid="B65-molecules-26-06057" ref-type="bibr">65</xref>]. The compounds with simple carboxylic acids in the side chain are classified as first generation penicillins [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>,<xref rid="B66-molecules-26-06057" ref-type="bibr">66</xref>]</p><p>The second generation penicillins consists of aminopenicillins such as <bold>42</bold>&#x02013;<bold>45</bold> (<xref rid="molecules-26-06057-f009" ref-type="fig">Figure 9</xref>). Introduction of the amino group, which will be protonated in acidic media, makes the compounds less acid labile [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. These penicilllins are active against Gram-positive as well as Gram-negative bacteria such as <italic toggle="yes">Haemolhillus influenza, E. coli</italic> and <italic toggle="yes">Proteus mirabilis</italic>. They have good bioavailability after oral administration [<xref rid="B20-molecules-26-06057" ref-type="bibr">20</xref>,<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>,<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. Ampicillin was the first penicillin with some activity against Gram-negative bacteria [<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>]. The introduction of a hydroxyl group in the para position of the phenylglycine residue of ampenicillin to give amoxicillin (<bold>44</bold>) improved the absorption after oral administration. Amoxicillin was marketed in 1964 [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>] and became one of the most widely prescribed penicillins [<xref rid="B67-molecules-26-06057" ref-type="bibr">67</xref>]. The aminopencillins were developed in the early 1960s [<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>].</p><p>Introduction of an acidic group into the side chain made the penicillins <bold>46</bold>&#x02013;<bold>48</bold> (<xref rid="molecules-26-06057-f010" ref-type="fig">Figure 10</xref>) clinically active against <italic toggle="yes">Pseudomonas</italic>
<italic toggle="yes">aeroginosa</italic> and some <italic toggle="yes">Klebsiella</italic> infections [<xref rid="B67-molecules-26-06057" ref-type="bibr">67</xref>] (third generation penicillins). Piperacillin (<bold>49</bold>) and mezlocillin (<bold>50</bold>) with bulky side chains are less sensitive toward &#x003b2;-lactamases and generate fourth generation penicillins [<xref rid="B66-molecules-26-06057" ref-type="bibr">66</xref>] (<xref rid="sec4dot6-molecules-26-06057" ref-type="sec">Section 4.6</xref>). These penicillins also were efficient in treatment of <italic toggle="yes">P. aeruginosa</italic> infections in immunocompromised patients [<xref rid="B67-molecules-26-06057" ref-type="bibr">67</xref>]. The drug is discontinued in the USA [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>]. The ureido group in the side chain of piperacillin enhances cell wall penetration of Gram.negative bacteria affording activity also against species belonging to <italic toggle="yes">Pesudomonas</italic>, <italic toggle="yes">Klebsiella</italic>, <italic toggle="yes">Enterobacter</italic> and <italic toggle="yes">Citrobacter</italic> [<xref rid="B20-molecules-26-06057" ref-type="bibr">20</xref>]. The drugs were developed in the late 1960s and the early 1970s [<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>].</p></sec><sec id="sec4dot5-molecules-26-06057"><title>4.5. Penicillin Hypersensitivity</title><p>Due to reaction with the &#x003b5;-amino group of lysine residues in proteins or disulfide formation between cysteine residues and degradation products of pencillins some patients may develop hypersensitivity following administration of penicillins. Fortunately most allergic reactions are benign [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. Polymerization of ampicillin molecules caused by reaction of the amino group and the &#x003b2;-lactam may also result in allergens [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>].</p></sec><sec id="sec4dot6-molecules-26-06057"><title>4.6. Penicillin Resistance</title><p>Microorganisms may become resistant to antibiotics targeting intracellular pathways by developing mechanisms pumping drugs out of the cells [<xref rid="B26-molecules-26-06057" ref-type="bibr">26</xref>]. This strategy is useless for Gram-positive bacteria for disarming penicillins, since their target is the crosslinking of the cell envelope outside the cell membrane [<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>]. However, some Gram-negative bacteria such as <italic toggle="yes">Pseudomonas aeruginosa, E. coli and Neisseria gonorrhoeae</italic> possess an outer membrane with multidrug effective efflux pumps [<xref rid="B68-molecules-26-06057" ref-type="bibr">68</xref>]. This outer membrane also might prevent small molecule-like antibiotics to penetrate to the penicillin-binding proteins [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>]. </p><p>Already Fleming discovered that the growth of <italic toggle="yes">Balantidium coli</italic> and several other bacteria was resistant to penicillin G [<xref rid="B40-molecules-26-06057" ref-type="bibr">40</xref>]. This observation was made before penicillin G (<bold>24</bold>) was taken to the clinic [<xref rid="B69-molecules-26-06057" ref-type="bibr">69</xref>,<xref rid="B70-molecules-26-06057" ref-type="bibr">70</xref>]. The resistant factor was transferred between different bacteria and was assumed to be an enzyme [<xref rid="B71-molecules-26-06057" ref-type="bibr">71</xref>]. This assumption was confirmed by the discovery of the &#x003b2;-lactamases. These enzymes efficiently neutralize penicillins by opening the &#x003b2;-lactam ring to give penicilloic acid (<bold>33</bold>). Cleavage of the &#x003b2;-lactam ring removes the antibacterial effect [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>,<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>,<xref rid="B72-molecules-26-06057" ref-type="bibr">72</xref>]. In principle, this is the same acylation of a serine residue that occurs, when penicillins inactivates penicillin-binding proteins. However, the &#x003b2;-lactamases are not essential for the microorganism. Fast hydrolysis reactivates the enzyme enabling ring opening of other &#x003b2;-lactam rings [<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>]. Genes conferring resistance to antibiotics have been found in 30,000-year old organisms suggesting that resistance against antibiotics was invented by Nature millennia before mankind developed drugs against infectious diseases [<xref rid="B70-molecules-26-06057" ref-type="bibr">70</xref>,<xref rid="B73-molecules-26-06057" ref-type="bibr">73</xref>]. &#x003b2;-Lactamases are widely distributed [<xref rid="B70-molecules-26-06057" ref-type="bibr">70</xref>,<xref rid="B71-molecules-26-06057" ref-type="bibr">71</xref>,<xref rid="B74-molecules-26-06057" ref-type="bibr">74</xref>,<xref rid="B75-molecules-26-06057" ref-type="bibr">75</xref>] and have been studied intensive because of their ability to neutralize the clinical effect of penicillins. In several pathogenic organisms, expression of &#x003b2;-lactamases is provoked by &#x003b2;-lactam antibiotics [<xref rid="B76-molecules-26-06057" ref-type="bibr">76</xref>]. The &#x003b2;-lactamases are divided into three classes A (penicillin-hydrolyzing), C (cephalosporin-hydrolyzing) and D (oxacillin-hydrolyzing) and Class B the metallo-&#x003b2;-lactamases [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>,<xref rid="B70-molecules-26-06057" ref-type="bibr">70</xref>,<xref rid="B72-molecules-26-06057" ref-type="bibr">72</xref>,<xref rid="B77-molecules-26-06057" ref-type="bibr">77</xref>]. Class C are primarily found in Gram-negative bacteria [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. The cleaving catalyzed by serine-&#x003b2;-lactamases (Class A, C and D) involves a serine residue in the &#x003b2;-lactamases which react with the &#x003b2;-lactam to give an ester of the serine (<xref rid="molecules-26-06057-sch004" ref-type="fig">Scheme 4</xref>). The enzyme penicillin complex is hydrolyzed to penicilloic acid (<bold>33</bold>) and reactivated &#x003b2;-lactamase [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>,<xref rid="B72-molecules-26-06057" ref-type="bibr">72</xref>,<xref rid="B77-molecules-26-06057" ref-type="bibr">77</xref>]. In the metallo-&#x003b2;-lactamases a hydroxide complexed with two zinc ions in the active site opens the &#x003b2;-lactam [<xref rid="B72-molecules-26-06057" ref-type="bibr">72</xref>]. A detailed mechanism of action of the different &#x003b2;-lactamases is given in some reviews [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>,<xref rid="B72-molecules-26-06057" ref-type="bibr">72</xref>]. </p><p>Two approaches were initiated to overcome resistance against penicillins (1) syntheses of penicillins that are resistant to &#x003b2;-lactamases (fourth generation penicillins) and (2) use of &#x003b2;-lactamase inhibitors (<xref rid="sec8-molecules-26-06057" ref-type="sec">Section 8</xref>). Other factors affecting the effect of antibiotics are population of bacteria and biofilm formation. Bacteria in biofilms are protected by the presence of extracellular polysaccharides [<xref rid="B78-molecules-26-06057" ref-type="bibr">78</xref>]. Old colonies of bacteria often have a slower rate of proliferation and consequently a less sensibility toward the antibiotics. In addition a higher population and diversity of bacteria increases the likeliness of &#x003b2;-lactamase producing species [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>].</p><p>Methicillin (<xref rid="molecules-26-06057-f011" ref-type="fig">Figure 11</xref>, <bold>51</bold>), introduced to the clinic in 1960, was the first penicillin with reduced &#x003b2;-lactamase sensitivity [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>,<xref rid="B57-molecules-26-06057" ref-type="bibr">57</xref>,<xref rid="B79-molecules-26-06057" ref-type="bibr">79</xref>]. Nafcillin (<bold>52</bold>) and oxacillin (<bold>53</bold>) with a steric bulk preventing hydrolysis followed later [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. Evidence for the importance of the bulky methoxy groups is revealed by the sensitivity of homologous penicillins toward &#x003b2;-lactamases. Introduction of a methylene group between the dimethoxyphenyl and the carbonyl group in methicillin (<bold>51</bold>) increases the sensitivity of the molecules toward &#x003b2;-lactamases [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. Methicillin (<bold>51</bold>) is not absorbed when given orally and cannot penetrate the outer membrane of Gram-negative bacteria8]. It is supplemented with nafcillin (<bold>52</bold>) and oxacillin (<bold>53</bold>) [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. A drawback of isoxazolyl penicillins such as <bold>53</bold> is a high protein binding lowering the serum concentration [<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>,<xref rid="B57-molecules-26-06057" ref-type="bibr">57</xref>]. Oxacillin (<bold>53</bold>) and nafcillin (<bold>52</bold>) are not approved in Japan, although they are standard therapy for treatment of infections with susceptible <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">S. epidermis</italic> in the major part of the world [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>]. Cefazolin is used instead [<xref rid="B80-molecules-26-06057" ref-type="bibr">80</xref>].</p><p>Another mechanism used by bacteria for gaining resistance against penicillins takes advantage of mutating the penicillin-binding proteins into enzymes distinguishing the penicillins from the endogenic substrate the D-Ala-D-Ala residue [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>,<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>,<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>,<xref rid="B81-molecules-26-06057" ref-type="bibr">81</xref>]. An example of such an enzyme is PBP2a produced by <italic toggle="yes">S. aureus</italic> [<xref rid="B43-molecules-26-06057" ref-type="bibr">43</xref>,<xref rid="B55-molecules-26-06057" ref-type="bibr">55</xref>]. Expression of PBP2a is the major reason for resistance against &#x003b2;-lactams. A surprising observation is that despite expression of PBP2a a synergistic effect of clavanulate, a &#x003b2;-lactamase inhibitor (<xref rid="sec8-molecules-26-06057" ref-type="sec">Section 8</xref>), and &#x003b2;-lactam antibiotics is observed for <italic toggle="yes">S. aureus</italic> [<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>]. </p><p>Penicillins substituted at C-6 were obtained by hypochlorite oxidation of penicillin G to give a intermediate chlorine derivative, which in methanol is converted into the &#x003b1;-methoxy derivative (<xref rid="molecules-26-06057-sch006" ref-type="fig">Scheme 6</xref>, <bold>54</bold>) [<xref rid="B82-molecules-26-06057" ref-type="bibr">82</xref>].</p><p>Development of the technique for 6-methoxylation enabled preparation of temocillin, developed in 1980 (<xref rid="molecules-26-06057-f012" ref-type="fig">Figure 12</xref>, <bold>55</bold>). Even though this compound has a long half live in the blood (about 5 h) the antibacterial activity is restricted to multiple resistant Gram-negative bacteria [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. Formidacillin (<bold>56</bold>) is highly potent against Gram-negative bacteria including <italic toggle="yes">Pseudomonas</italic> sp. and has some activity against <italic toggle="yes">Streptococcus</italic> sp. but none against <italic toggle="yes">Staphylococcus</italic> sp3]. The compound, however, never was approved as a drug by the FDA. </p><p>The ureidopenicillins azlocillin (<xref rid="molecules-26-06057-f013" ref-type="fig">Figure 13</xref>, <bold>57</bold>), mezlocillin (<bold>58</bold>) and piperazillin (<bold>59</bold>) were developed in the 1970s. They are efficient for treatment of infections with <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Klebsiella</italic> and some <italic toggle="yes">Enterobacter</italic> species. Unfortunately, they have a poor effect on infections of <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Enterobacter</italic> and <italic toggle="yes">Salmonella</italic> species [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B83-molecules-26-06057" ref-type="bibr">83</xref>].</p><p>Since the 1970s, very few new antibacterial drugs possessing the penam carbon skeleton have been introduced. A search in To Market To Market from 2019 to 2006 (Annual Reports in Medicinal Chemistry and Medicinal Chemistry Reviews) revealed no penicillins brought to the market. In contrast, several drugs in which penicillins are combined with &#x003b2;-lactamase inhibitors has been approved [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>,<xref rid="B84-molecules-26-06057" ref-type="bibr">84</xref>].</p></sec><sec id="sec4dot7-molecules-26-06057"><title>4.7. Penicillin Prodrugs</title><p>Prodrugs, in which the carboxylic acid has been masked, were used for improving absorption of ampicillin (<bold>42</bold>). The first prodrug was pivampicillin (<xref rid="molecules-26-06057-f014" ref-type="fig">Figure 14</xref>, <bold>60</bold>) marketed by Leo Pharma [<xref rid="B57-molecules-26-06057" ref-type="bibr">57</xref>] in the 1970s [<xref rid="B85-molecules-26-06057" ref-type="bibr">85</xref>]. Administration of pivampicillin afforded three time higher serum concentration of ampicillin and higher maximal serum concentration after one hour than after administration of an equimolar amount of ampicillin [<xref rid="B86-molecules-26-06057" ref-type="bibr">86</xref>]. The pivalic acid released after cleavage of pivampicillin (<bold>58</bold>) to give ampicillin (<bold>42</bold>) might have an effect on the carnitine plasma level [<xref rid="B87-molecules-26-06057" ref-type="bibr">87</xref>]. Additionally, talampicillin (<bold>61</bold>) [<xref rid="B88-molecules-26-06057" ref-type="bibr">88</xref>], bacampicillin (<bold>62</bold>) [<xref rid="B89-molecules-26-06057" ref-type="bibr">89</xref>] and lenampenicillin (<bold>63</bold>) [<xref rid="B90-molecules-26-06057" ref-type="bibr">90</xref>] were absorbed efficiently.</p></sec></sec><sec id="sec5-molecules-26-06057"><title>5. Cephalosporins</title><sec><title>Discovery and Production of Cephalosporins</title><p>Cephalosporins contain the backbone cephem (<xref rid="molecules-26-06057-f004" ref-type="fig">Figure 4</xref>). Cephalosporin C was isolated from a wild strain of <italic toggle="yes">Cephalosporium</italic> in 1945 [<xref rid="B91-molecules-26-06057" ref-type="bibr">91</xref>]. The molecular formula was published in 1955 [<xref rid="B91-molecules-26-06057" ref-type="bibr">91</xref>,<xref rid="B92-molecules-26-06057" ref-type="bibr">92</xref>] and the constitution <bold>64</bold> (<xref rid="molecules-26-06057-f015" ref-type="fig">Figure 15</xref>) in 1961 [<xref rid="B93-molecules-26-06057" ref-type="bibr">93</xref>]. An X-ray analysis confirmed the constitution <bold>64</bold> [<xref rid="B94-molecules-26-06057" ref-type="bibr">94</xref>]. Today <italic toggle="yes">Acremomium chrysogenum</italic> (formerly <italic toggle="yes">Cephalosporium acremomium</italic>) is primarily used for production of cephalosporins. Similar stereochemistry at the &#x003b2;-lactam ring in the penicillins and cephalosporins was established by a rearrangement of phenoxymethyl penicillin sulfoxide to a cephalosporin without changing the stereochemistry in the &#x003b2;-lactam ring (<xref rid="molecules-26-06057-sch007" ref-type="fig">Scheme 7</xref>) [<xref rid="B95-molecules-26-06057" ref-type="bibr">95</xref>].</p><p>The naturally occurring cephalosporin <bold>64</bold> is converted to the free amine by reaction of the protected acid with phosphorous pentachloride followed by hydrolysis of the intermediate iminoether (<xref rid="molecules-26-06057-sch008" ref-type="fig">Scheme 8</xref>) [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>,<xref rid="B96-molecules-26-06057" ref-type="bibr">96</xref>,<xref rid="B97-molecules-26-06057" ref-type="bibr">97</xref>]. Procedures for enzymatic cleavage of the amide avoiding hazardous reagents have also been developed [<xref rid="B97-molecules-26-06057" ref-type="bibr">97</xref>].</p><p>From a biosynthetic point of view, cephalosporin-like penicillin is a non-ribosomal tripeptide originating from peptide &#x003b6;-D-aminoadipidoyl-L-cysteinoyl-D-isovalerine. However, after formation of the penicillin (<xref rid="molecules-26-06057-sch005" ref-type="fig">Scheme 5</xref>) the 2 position in D-2-aminoadipic residue is isomerized, a radical formation at one of the methyl groups in valine and a ring expansion occurs to give the cephalosporin nucleus. After oxidation and acetylation of the methyl group cephalosporin C (<bold>61</bold>) is formed (<xref rid="molecules-26-06057-sch009" ref-type="fig">Scheme 9</xref>) [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>,<xref rid="B54-molecules-26-06057" ref-type="bibr">54</xref>]. The penicillin-cephalosporin rearrangement described in <xref rid="molecules-26-06057-sch007" ref-type="fig">Scheme 7</xref> shows resemblance to the biosynthesis of cephalosporin from penicillin N.</p><p>Like the pencillins the cephalosporins are classified in generations [<xref rid="B66-molecules-26-06057" ref-type="bibr">66</xref>]. The first generation of cephalosporins (narrow spectrum) consists drugs such as cephalexin (<xref rid="molecules-26-06057-f016" ref-type="fig">Figure 16</xref>, <bold>65</bold>), cefadrine (<bold>66</bold>) and cefadroxil (<bold>67</bold>). First generation drugs have activity against Gram-positive bacteria such as <italic toggle="yes">Staphylococcus aurea, Streptococcus</italic> species, even though they are expressing &#x003b2;-lactamases, and a few Gram-negative bacteria e.g., <italic toggle="yes">E. coli, H. influenza</italic> and <italic toggle="yes">Klebsiella</italic> species. They are used against uncomplicated skin and soft tissue infections [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>,<xref rid="B98-molecules-26-06057" ref-type="bibr">98</xref>,<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. Drugs belonging to second generation (intermediate spectrum activity) are cefalclor (<bold>68</bold>) and cefuroxime (<bold>69</bold>). They possess some activity against aerobic Gram-negative bacteria such as species of <italic toggle="yes">Moraxella</italic>, <italic toggle="yes">Neisseria</italic>, <italic toggle="yes">Salmonella</italic>, and <italic toggle="yes">Shigella</italic> [<xref rid="B98-molecules-26-06057" ref-type="bibr">98</xref>,<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. They are used against upper and lower respiratory tract infections, sinusitis, and otitis media [<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. </p><p>Examples of third generation (broad spectrum activity) cephalosporins are cefotaxime (<xref rid="molecules-26-06057-f017" ref-type="fig">Figure 17</xref>, <bold>70</bold>), ceftazidime (<bold>71</bold>), ceftriaxone (<bold>72</bold>), and ceftizoxime (<bold>73</bold>) [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B98-molecules-26-06057" ref-type="bibr">98</xref>,<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. The introduction of a methoxime group (<bold>74</bold>&#x02013;<bold>76</bold>) makes the compound substrate for a tripeptide transporter in the intestinal mucosoal membrane [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. They have good activity against most Gram-negative bacteria and are less sensitive toward &#x003b2;-lactamase [<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. In addition, they possess some activity toward Gram-positive bacteria and some methicillin resistant strains [<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. Cefepime (<bold>74</bold>), cefpirome (<bold>75</bold>), and cefquinome (<bold>76</bold>) belong to the fourth generation of cephalosporins (broad spectrum activity). By introduction of an ammonium ion the ability to penetrate the outer membrane in Gram-negative bacteria is increased [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. They are effective against several resistant bacteria such as Gram-positive cocci, <italic toggle="yes">Streptococcus pneumoniae,</italic> Entero-bacteriaceae, and <italic toggle="yes">Pseudomonas aeruginosa</italic> strains. They are used for treatment of meningitis [<xref rid="B98-molecules-26-06057" ref-type="bibr">98</xref>,<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. Fifth generation cephalosporins (extended spectrum activity) encompasses ceftobiprole (<bold>77</bold>) and ceftraoline (<bold>78</bold>). Ceftobiprole (<bold>77</bold>) is a very broad spectrum cephalosporin with activity against Gram-positive cocci, including MRSA and methicillin resistant <italic toggle="yes">Staphylococcus epidermidis</italic> (MRSE), penicillin-resistant <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Enterococcus faecalis</italic> and many Gram-negative bacilli including &#x003b2;-lactamases groups C producing <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. Cefepime (<bold>74</bold>) has a &#x003b3;-aminobutyric acid residue in the structure meaning that after penetrating the blood-brain-barrier it might have neurotoxic effects [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. Ceftaroline fosamil (<bold>78</bold>) is an example of a fifth generation cephalosporin. It is used against multidrug-resistant <italic toggle="yes">Staphylococcus aureus</italic>, including MRSA, VRSA, and VISA [<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>]. Ceftaroline fosamil is a water soluble prodrug which in the organism is dephosphorylated to yield ceftaroline [<xref rid="B100-molecules-26-06057" ref-type="bibr">100</xref>]. Ceftaroline fosamil was approved by the FDA (2010) and the European Medical Agency (2012).</p><p>Cephalosporin hypersensitivity is unusual. The seldom cases are in general benign. Cross reaction between penicillin allergy and cephalosporin allergy has not been observed [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>].</p></sec></sec><sec id="sec6-molecules-26-06057"><title>6. Carbapenems</title><p>Carbapenems (<xref rid="molecules-26-06057-f004" ref-type="fig">Figure 4</xref>) are characterized by a backbone consisting of the same bicyclic ring system as penicillin, but possessing a double bond between C-2 and C-3 and a carbon atom in the 1 position. The two hydrogen atoms at C-5 and C-6 are trans disposed in clinical important carbapenems in contrast to the cis disposed C-5 and C-6 hydrogens in penicillins and the C-6 and C-7 cis disposed hydrogens in cephalosporins [<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>]. This might explain a lower sensitivity toward some &#x003b2;-lactamases [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>]. The first isolated carbapenem was olivanic acid isolated from the broth of <italic toggle="yes">Streptomyces clavuligerus</italic> (<xref rid="molecules-26-06057-f018" ref-type="fig">Figure 18</xref>, <bold>79</bold>). Due to penetration problems this compound was not pursued [<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>]. The <italic toggle="yes">R</italic>-1-hydroxyethyl group at C-6 appears to be optimal for an antibiotic effect of carbapenems. As described in <xref rid="sec3-molecules-26-06057" ref-type="sec">Section 3</xref> and <xref rid="sec4-molecules-26-06057" ref-type="sec">Section 4</xref> the sidechain at C-6 in peniclllins and C-7 in cephalosporins might be substituted to improve the clinical effect [<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>]. Thienamycin (<bold>80</bold>) was isolated from the broth of <italic toggle="yes">Streptomyces cattleya</italic> [<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>]. The presence of an electrophilic &#x003b2;-lactam ring and a nucleophilic amino group makes thienamycin unsuitable as a drug because of intermolecular amid formation [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>].</p><p>In general, the in vitro spectrum of activity of the carbapenems is broader than that of penicillins and cephalosporins. Imipenem (<bold>81</bold>), penipenem (<bold>82</bold>) and doripenem (<bold>86</bold>) are used against infections with Gram-positive bacteria. The introduction of the amidine group in imipenem (<bold>81</bold>) ensures protonation at physiologic pH preventing a cleavage of the &#x003b2;-lactam ring [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. Imipenem was approved as a drug in 1985 [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. Biapenem (<bold>83</bold>), meropenem (<bold>84</bold>), ertapenem (<bold>85</bold>) and doripenem (<bold>86</bold>) to some extend show activity against Gram-negative bacteria. Meropenem was approved in 1996 [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. In combination, meropenem (<bold>84</bold>) and the &#x003b2;-lactamase inhibitor clavulanic acid (<xref rid="sec3dot1-molecules-26-06057" ref-type="sec">Section 3.1</xref>) have an effect on methicillin drug resistant <italic toggle="yes">Mycobacterium tuberculosuis</italic>, a bacterium otherwise resistant toward &#x003b2;-lactam antibiotics [<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>]. The presence of a &#x003b2;-methyl group at C-1 prevents the carbapenems from being hydrolyzed in the kidney by renal dihydropeptidase-1 [<xref rid="B102-molecules-26-06057" ref-type="bibr">102</xref>] and consequently prolong the effect by reuptake [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B103-molecules-26-06057" ref-type="bibr">103</xref>]. Doripenem (<bold>86</bold>) and ertapenem (<bold>85</bold>) were approved in 2007 and 2001, respectively [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>].</p><p>In contrast to other &#x003b2;-lactam antibiotics, large scale production of carbapenems is based on synthesis and not fermentation [<xref rid="B104-molecules-26-06057" ref-type="bibr">104</xref>]. Pioneering efforts making the compounds available for clinical use were performed by the Merck group [<xref rid="B105-molecules-26-06057" ref-type="bibr">105</xref>,<xref rid="B106-molecules-26-06057" ref-type="bibr">106</xref>,<xref rid="B107-molecules-26-06057" ref-type="bibr">107</xref>] supported by others [<xref rid="B108-molecules-26-06057" ref-type="bibr">108</xref>]. Review of methods for constructing the azetidinone intermediates have been published [<xref rid="B109-molecules-26-06057" ref-type="bibr">109</xref>].</p><p>Different strategies for developing resistance are (1) reducing the sensitivity of penicillin-binding enzymes for carbapenems by mutation, (2) altering porins, expression of efflux pumps or (3) expression of &#x003b2;-lactamases. In Gram-positive cocci resistance is typically caused by mutation of penicillin-binding proteins. In Gram-negative rods expression of &#x003b2;-lactamases, porin change or/and alterations of penicillin-binding proteins makes the bacteria more resistant [<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>]. </p><p>In the clinic treatment of patients with community-acquired pneumonia with meropenem (<bold>84</bold>), ertapenem (<bold>85</bold>) or imipenem (<bold>81</bold>) combined with cilastatin, a dihydropeptidase-1 inhibitor has shown overall god response [<xref rid="B103-molecules-26-06057" ref-type="bibr">103</xref>]. Patients suffering from nosocomial pneumonia responded more positive after treatment with meropenem (<bold>84</bold>) than after treatment with ceftazidime (<bold>71</bold>) combined with tobramycin [<xref rid="B103-molecules-26-06057" ref-type="bibr">103</xref>]. Carbapenems also have shown good effects on hospital-acquired pneumonia and cystic fibrosis [<xref rid="B103-molecules-26-06057" ref-type="bibr">103</xref>]. Complicated intra-abdominal infections have been treated successfully with imipenem (<bold>81</bold>), meropenem (<bold>84</bold>), ertapenem (<bold>85</bold>) and doripenem (<bold>86</bold>) [<xref rid="B103-molecules-26-06057" ref-type="bibr">103</xref>]. Meropenem (<bold>84</bold>) and doripenem (<bold>86</bold>) as single therapy and iminipem (<bold>81</bold>) combined with cilastatin have been shown to have good effects on urinary tract infections [<xref rid="B103-molecules-26-06057" ref-type="bibr">103</xref>]. Ertapenem (<bold>85</bold>), and meropenem (<bold>84</bold>) in combination with cilastatin have shown positive response in treatment of complicated skin and soft tissue infections [<xref rid="B103-molecules-26-06057" ref-type="bibr">103</xref>]. The carbapenems are classified into three groups: Group 1 such as ertapenem (<bold>85</bold>) broad spectrum carbapenems with limited activity against non-fermentative Gram-negative bacilli but suitable for treatment of community-acquired infections. Group 2: imipenem (<bold>81</bold>), meropenem (<bold>84</bold>) and doripenem (<bold>86</bold>) are broad spectrum carbapenems, with activity against non-fermentative Gram-negative bacilli. They have less sensitivity to base promoted hydrolysis in solution. Group 3 carbapenems are clinical activity against resistant <italic toggle="yes">S. aureus</italic>. The latter group is still under development [<xref rid="B110-molecules-26-06057" ref-type="bibr">110</xref>].</p><p>A drawback of the carbapenems is poor oral activity [<xref rid="B110-molecules-26-06057" ref-type="bibr">110</xref>]. To overcome this problem a prodrug, tebipenem pivoxil (<xref rid="molecules-26-06057-f019" ref-type="fig">Figure 19</xref>, <bold>88</bold>) was prepared. The prodrug strategy is analogous to the principle used for pivampicillin (<bold>59</bold>) the prodrug of ampicillin (<bold>42</bold>). At the present this compound is under development as an orally active drug against pathogens causing respiratory tract infections [<xref rid="B111-molecules-26-06057" ref-type="bibr">111</xref>]. Sanfetrinem (<bold>89</bold>) is the first tricyclic carbapenem. It possesses several interesting in vitro activities [<xref rid="B110-molecules-26-06057" ref-type="bibr">110</xref>].</p></sec><sec id="sec7-molecules-26-06057"><title>7. Thiopenems</title><p>The synthesis of faropenem (<xref rid="molecules-26-06057-f020" ref-type="fig">Figure 20</xref>, <bold>90</bold>) was published in a patents and Chinese journals between 2000 and 2010 [<xref rid="B112-molecules-26-06057" ref-type="bibr">112</xref>]. The prodrug faropenem medoximil (<bold>91</bold>) is well absorbed after oral administration [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. A synthesis of sulopenem (<bold>92</bold>) is published [<xref rid="B113-molecules-26-06057" ref-type="bibr">113</xref>]. The key reaction is a triethoxyphosphine catalyzed thiopenem cyclization of the intermediate <bold>94</bold> (<xref rid="molecules-26-06057-sch010" ref-type="fig">Scheme 10</xref>). Sulopenem is also administered as a prodrug sulopenem etzadrozil (<bold>93</bold>) [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. Introduction of a C-C double bond in the thiazolidine ring and the presence of a sulfur atom reduce ring tensions and reduce the reactivity of the &#x003b2;-lactam ring. The thiopenems are active against Gram-positive <italic toggle="yes">cocci</italic>, <italic toggle="yes">Streptococcus pneumoniae</italic> and Gram-negative bacteria but not against <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B114-molecules-26-06057" ref-type="bibr">114</xref>]. No thiopenem are found on the homepage of the European Medical Agency (August 2021) indicating that no thiopenem is approved as a drug. The FDA previously have rejected the registration of faropenem [<xref rid="B115-molecules-26-06057" ref-type="bibr">115</xref>].</p></sec><sec id="sec8-molecules-26-06057"><title>8. Monobactams</title><p>The monobactam goup is the last discovered types of &#x003b2;-lactams. The first description is in a Japanese patent from 1979. For structure elucidation sulfazecin (<xref rid="molecules-26-06057-sch011" ref-type="fig">Scheme 11</xref>, <bold>95</bold>) isolated from the broth of <italic toggle="yes">Pseudomonas</italic> species was converted to D-&#x003b3;-glytamyl-D-alanylamide and 2-oxo-3-sulfaminopropionic acid by hydrolysis with M hydrochloric acid [<xref rid="B116-molecules-26-06057" ref-type="bibr">116</xref>,<xref rid="B117-molecules-26-06057" ref-type="bibr">117</xref>]. The compound showed varying MIC from 0.4 &#x000b5;g/mL for <italic toggle="yes">Escherichia coli</italic> to 800 &#x000b5;g/mL for <italic toggle="yes">Bacillus cereus</italic>. Several other monobactams were isolated from <italic toggle="yes">Chromobacterium violaceum</italic> and other bacteria [<xref rid="B117-molecules-26-06057" ref-type="bibr">117</xref>].</p><p>Aztreonam (<xref rid="molecules-26-06057-f021" ref-type="fig">Figure 21</xref>, <bold>96</bold>) is an example of a monbactam introduced on the market. The drug is derived from sulfazecin (<bold>95</bold>) by removal of the methoxy group and introduction of one of the side chain known from other &#x003b2;-lactam antibiotics [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. It easily penetrates the outer membrane of Gram-negative aerobes such as <italic toggle="yes">Pseudomonas aeruginosa</italic>. Poor absorption from the gastro-intestinal duct makes intramuscular injection the preferred way of administration [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B118-molecules-26-06057" ref-type="bibr">118</xref>].</p><p>Carbapenemases particularly efficient in cleaving carbapenems have been discovered [<xref rid="B77-molecules-26-06057" ref-type="bibr">77</xref>].</p></sec><sec id="sec9-molecules-26-06057"><title>9. &#x003b2;-Lactamase Inhibitors</title><p>By far the major reason for resistance of bacteria against &#x003b2;-lactam antibiotics is expression of &#x003b2;-lactamases [<xref rid="B72-molecules-26-06057" ref-type="bibr">72</xref>,<xref rid="B77-molecules-26-06057" ref-type="bibr">77</xref>,<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>]. An important strategy for combating pathogenic resistant bacteria therefor is to inactivate &#x003b2;-lactamases by co-administration of &#x003b2;-lactam antibiotic drugs and &#x003b2;-lactamase inhibitors. Carbapenems are less sensitive to &#x003b2;-lactamases due to the different stereochemistry on the lactam ring [<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>]. The use of combination therapy is complicated by different absorption, metabolism and kinetic of the antibiotic and the &#x003b2;-lactamases inhibitor. In principle, these parameters are unique for every patient. In most cases, however, the combination drugs are distributed in fixed ratios [<xref rid="B120-molecules-26-06057" ref-type="bibr">120</xref>]. The inhibitors might be of the three well-known types the &#x003b2;-lactam type, the diazabicyclooctane type and the boronic acid type. Clinical results for the use of some approved &#x003b2;-lactam-&#x003b2;-lactamase inhibitor combinations have been reviewed [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>,<xref rid="B120-molecules-26-06057" ref-type="bibr">120</xref>].</p><sec id="sec9dot1-molecules-26-06057"><title>9.1. The &#x003b2;-Lactam Type of &#x003b2;-Lactamase Inhibitors</title><p>The first inhibitor to be discovered was clavulanic acid (<xref rid="molecules-26-06057-f022" ref-type="fig">Figure 22</xref>, <bold>97</bold>). It was discovered in a <italic toggle="yes">Streptomyces</italic> broth because growth of a penicillin-resistant <italic toggle="yes">Klebsiella aerogenes</italic> in a medium containing penicillin G (<bold>24</bold>) was inhibited. Thus, the presence of clavulanic acid (<bold>97</bold>) in the broth made <italic toggle="yes">Klebsiella aerogenes</italic> sensitive toward penicillin. [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>,<xref rid="B121-molecules-26-06057" ref-type="bibr">121</xref>,<xref rid="B122-molecules-26-06057" ref-type="bibr">122</xref>]. The nucleus is an oxapenam isosteric to the carbapenam. The absence of a C-6 side chain deprives the molecule from a significant antibiotic effect but gives the molecule high affinity for &#x003b2;-lactamases [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. Clavulanic acid inhibits serine &#x003b2;-lactamases but not metallo-&#x003b2;-lactamases [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>]. Two combinations of amoxicillin (<bold>44</bold>) and clavulanic acid (<bold>97</bold>) in two different ratios (marketed as augmentin and timentin) are approved by the U.S. Food and Drug Administration (FDA) for treatment of infections with e.g., <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Haemophilus influenza, Moraxella catarrhailis, Klebsiella</italic> spp., <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">Escherichia coli</italic> [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>]. Sulbactam (<bold>98</bold>) is a thiopenamdioxide with no C-6 side chain depriving an antibiotic effect [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>]. It is approved to be used in combinations in different ratios with ampicillin (<bold>42</bold>) and cefoperazone for treatment of infections of <italic toggle="yes">S. aureus, E. coli, Klebsiella</italic> spp. and <bold><italic toggle="yes">Enterobacter</italic></bold>
<italic toggle="yes">cloaceae</italic> [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>]. In 1993 tazocin a combination of tazobactam (<bold>99</bold>) and piperacilllin (<bold>49</bold>) was introduced to treat infections with <italic toggle="yes">S. aureus, S. pneumoniae</italic> and <italic toggle="yes">E. coli</italic> [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>]. Enmetazobactam (<bold>100</bold>) possesses a quaternary ammonium group, which together the carboxylate result in a net neutral compound with enhanced cell permeability. The enzyme group also increases affinity to spectrum &#x003b2;-lactamase of class A and D [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>]. The &#x003b2;-lactamase synergistically augment the effects of penicillins sensitive to &#x003b2;-lactamases [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>].</p><p>Sulbactam (<bold>98</bold>) is asumed to react irreversible with the &#x003b2;-lactamase as illustrated in <xref rid="molecules-26-06057-sch012" ref-type="fig">Scheme 12</xref> [<xref rid="B123-molecules-26-06057" ref-type="bibr">123</xref>]:</p></sec><sec id="sec9dot2-molecules-26-06057"><title>9.2. The Diazabicyclooctane Type of &#x003b2;-Lactamase Inhbitors</title><p>Design of the diazabicyclooctane group was inspired by the naturally occurring lactivicin (<xref rid="molecules-26-06057-sch013" ref-type="fig">Scheme 13</xref>, <bold>101</bold>) isolated from the broth of <italic toggle="yes">Empedobacter lactamgenus</italic> and <italic toggle="yes">Lysobacter albus</italic> [<xref rid="B124-molecules-26-06057" ref-type="bibr">124</xref>,<xref rid="B125-molecules-26-06057" ref-type="bibr">125</xref>]. The compound is a non-ribosomal dipeptide, in which the skeleton is derived from a serine and a glutamic acid. In solution an equilibrium between the two epimers at the quaternary carbon in the isoxazolidin-2-one ring is established [<xref rid="B126-molecules-26-06057" ref-type="bibr">126</xref>]. Even though lactivicin is not a &#x003b2;-lactam but an isoxazilidin-2-one it stills react with penicillin-binding proteins and was found to be active against <italic toggle="yes">Streptococcus pneumoniae</italic> strains. The compound is highly active against Gram-positive bacteria and has modest activity against Gram-negative bacteria [<xref rid="B125-molecules-26-06057" ref-type="bibr">125</xref>]. Other derivatives such as the phenoxy derivative <bold>102</bold> were found to be active against several clinically relevant Gram-negative strains such as <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>]. The discovery of lactivicins ability to acylate penicillin-binding peptides led to test of other heterocycles to find new heterocycles able to inactivate penicillin-binding peptides.</p><p>Soon it was observed that the imidazolin-2-one residue in the diazabicyclo[3.2.1}octane also reacts with &#x003b2;-lactamases. Consequently, synthesis and testing of similar compounds was initiated in several pharmaceutical companies. As result of these efforts avibactam (<xref rid="molecules-26-06057-f023" ref-type="fig">Figure 23</xref>, <bold>103</bold>) was discovered [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>]. Avibactam has antibacterial effect but is approved for clinical use in combination with ceftazidime (<bold>71</bold>) (Avycaz) [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>,<xref rid="B127-molecules-26-06057" ref-type="bibr">127</xref>]. A diazbicyclooctane such as <bold>104</bold> has antibacterial activity [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>].</p><p>The mechanism for the reaction of avibactam (<bold>103</bold>) with penicillin-binding peptides (PBP) is depicted in <xref rid="molecules-26-06057-sch014" ref-type="fig">Scheme 14</xref>. Like in the &#x003b2;-lactams a reactive amide, in this case a carbamate, is the functional group. The presence of a sulfate ester makes the nitrogen a better leaving group. The hydrophilic carbamoyl group makes a more stable complex with the serine-&#x003b2;-lactamases than do other &#x003b2;-lactam lactamase inhibitors such as clavulanic acid [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>]. The carbamoyl-lactamase complex is surprisingly stable [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>].</p><p>Ceftazidime (<bold>71</bold>) and avibactam (<bold>103</bold>) as combination therapy has been introduced to meet the urgent need for antipseudomonal antibiotics [<xref rid="B128-molecules-26-06057" ref-type="bibr">128</xref>].</p></sec><sec id="sec9dot3-molecules-26-06057"><title>9.3. Boronic Acid &#x003b2;-Lactamase Inhibitors</title><p>The first boronic acid &#x003b2;-lactamase inhibitor to be used in the clinic was vaborbactam (<xref rid="molecules-26-06057-f024" ref-type="fig">Figure 24</xref>, <bold>105</bold>) in combination with meropenenem (<bold>84</bold>). The 1:1 combination is marketed as varbomere cures urinary tracts infections caused by Enterobacteriaceae resistant against the normally used drugs such as cephalosporins, fluoroquinolones and carbapenems [<xref rid="B129-molecules-26-06057" ref-type="bibr">129</xref>]. Varbomere is also used against infections of the kidneys (pyelonephritis) [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>]. Resistance is caused by expression of &#x003b2;-lactamases [<xref rid="B129-molecules-26-06057" ref-type="bibr">129</xref>]. Boronic acid mimics the carbonyl group in the &#x003b2;-lactam ring. The mechanism of action involves a covalent binding of the boron atom with the active site serine hydroxyl group (<xref rid="molecules-26-06057-f025" ref-type="fig">Figure 25</xref>). Vaborbactam inhibits class A and class C serine &#x003b2;-lactamases [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>]. The affinity for the enzyme can be adjusted by modifying the side chain on the boron containing ring [<xref rid="B130-molecules-26-06057" ref-type="bibr">130</xref>].</p><p>Taniborbactam (<bold>106</bold>) is the first serine-&#x003b2;-lactamase inhibitor, which inhibits all the three groups of serine-&#x003b2;-lactamases, A, C and D and even some metallo-&#x003b2;-lactamase inhibitors, group B [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>,<xref rid="B120-molecules-26-06057" ref-type="bibr">120</xref>]. An apparently successful clinical trial 3 randomized double blind study comparing taniborlactam-cefepime versus meropenem is performed [<xref rid="B120-molecules-26-06057" ref-type="bibr">120</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec10-molecules-26-06057"><title>10. Conclusions and Perspectives</title><p>The observation that the major fall in the death rate caused by infectious diseases occurred before the introduction of antibiotic drugs with improved hygiene and sanitation [<xref rid="B1-molecules-26-06057" ref-type="bibr">1</xref>] should not lead to the misconception that these drugs have not revolutionized the treatment of bacterial infections. The first antibiotic drugs, salvarsan and sulfonamides, had a limited spectrum of activity but still enabled physicians to cure previous untreatable diseases. Introduction of &#x003b2;-lactam antibiotics has significantly improved the armamentarium for treatment to such an extent that today less than 1 % of deaths are caused by of infectious diseases in high income countries [<xref rid="B2-molecules-26-06057" ref-type="bibr">2</xref>,<xref rid="B72-molecules-26-06057" ref-type="bibr">72</xref>,<xref rid="B123-molecules-26-06057" ref-type="bibr">123</xref>]. However, development of extended spectrum resistant bacteria threatens the present state of control of infectious diseases [<xref rid="B84-molecules-26-06057" ref-type="bibr">84</xref>]. In particular, a rapid spread of carbapenem resistant <italic toggle="yes">Pseudomonas aruginosa</italic> and extended spectrum resistant &#x003b2;-lactamase expressing species of Enterobacteriaceae is alarming [<xref rid="B21-molecules-26-06057" ref-type="bibr">21</xref>]. In South Europe, 25&#x02013;50% of <italic toggle="yes">p. aeruginosa</italic> strains are carbapenem resistant. Similar alarming observations have been made for <italic toggle="yes">Acinetobacter baumanii</italic> and <italic toggle="yes">S. aureus</italic> [<xref rid="B131-molecules-26-06057" ref-type="bibr">131</xref>]. A meta-analysis has revealed that 14% of healthy individuals carry extended spectrum resistant &#x003b2;-lactamase producing bacteria. This number might increase [<xref rid="B21-molecules-26-06057" ref-type="bibr">21</xref>]. In 2016 the annual mortality caused by resistant bacteria was estimated to 23,000 persons in the USA [<xref rid="B70-molecules-26-06057" ref-type="bibr">70</xref>]. Treatment of patients infected with multi resistant bacteria is time consuming, expensive and risky. An analysis of 1391 patients infected with multi resistant bacteria hospitalized at Chicago Teaching Hospital disclosed (1) an excess duration of hospitalization estimated to between 6.4 to 12.7 days (2) additional costs of USD 18,600&#x02013;29,000 for each patient (3) a mortality of 6.5% and (4) social costs of USD 11&#x02013;15 millions [<xref rid="B132-molecules-26-06057" ref-type="bibr">132</xref>]. An estimate predicts that in 2050 extended spectrum resistant bacteria cause 10 million deaths and will drain the society for USD 100 trillion each year [<xref rid="B21-molecules-26-06057" ref-type="bibr">21</xref>].</p><p>A part of the problem origins in misuse of and overuse of antibiotics in human and veterinary medicine. Use of antibiotics to increase growth rate of livestock should be avoided. Recent estimates suggest that 70% of antibiotics are used in animals [<xref rid="B131-molecules-26-06057" ref-type="bibr">131</xref>]. Public education should prevent use of antibiotics to treat infections caused by virus like common cold. Viral infections are not affected by antibiotics. Sale of antibiotics over the counter might have led to misuse and should be prohibited. Already Alexander Fleming in 1945 in his Nobel lecture warned against the risk of resistance by misuse of antibiotic drugs [<xref rid="B131-molecules-26-06057" ref-type="bibr">131</xref>].</p><p>Despite spreading resistance only few new antibiotics are currently marketed, as illustrated in <xref rid="molecules-26-06057-t001" ref-type="table">Table 1</xref> [<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>].</p><p>Many multinational pharmaceutical companies have stopped their projects for developing antibiotics [<xref rid="B70-molecules-26-06057" ref-type="bibr">70</xref>,<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>]. The vast majority of the drugs approved in the period 2014 to 2020 originated in well-known classes of antibiotics. Some innovative developments are seen in the field of &#x003b2;-lactamase inhibitors [<xref rid="B84-molecules-26-06057" ref-type="bibr">84</xref>]. The poor return of investment compared to other drugs such as drugs for diabetes or cancer is demotivating. The sale of marketed antibiotic drugs the first two years afforded a sale of between USD 20 million (orbactiv, a glycopeptide for treatment of severe infection with Gram-positive bacteria) to USD 80 million (avycaz (<xref rid="sec9dot2-molecules-26-06057" ref-type="sec">Section 9.2</xref>)). In contrast, the sale of other medicines varied between USD 600 million (linzess/linacloride for treatment of constipation) and USD 1,500 million (januvia/sitagliptin for treatment of type 2 diabetes). The present spreading of resistance could result in a situation with increased mortality caused by communicative infections. To prevent such a situation the US Congress passed legislation in 2012 to create incentives for developing drugs [<xref rid="B20-molecules-26-06057" ref-type="bibr">20</xref>,<xref rid="B84-molecules-26-06057" ref-type="bibr">84</xref>]. Common for the antibiotic drugs approved in the period 2011 to 2017 is that they all have been marketed by small pharmaceutical companies; even though some of drugs were developed by international companies. Thus, small companies have a niche for developing and marketing antibiotic drugs. The latest marketed drugs are combination therapy combining &#x003b2;-lactams with &#x003b2;-lactamase inhibitors e.g., ceftazidime (<bold>70</bold>) in combination with avibactam (<bold>103</bold>) [<xref rid="B120-molecules-26-06057" ref-type="bibr">120</xref>,<xref rid="B134-molecules-26-06057" ref-type="bibr">134</xref>]. No compounds with a new mechanism of action have been marketed.</p><p>Beside antibiotics, vaccination is an additional tool to control communicative diseases. The first vaccination was performed in 1796 when Jenner injected lymph from a cow-pox vesicle into a boy. The boy developed a cow-pox pustule and became protected against smallpox [<xref rid="B3-molecules-26-06057" ref-type="bibr">3</xref>]. Today vaccination has become an important tool for preventing diseases. It has led to the eradication of smallpox, the elimination of polio from most countries, and the control of other diseases, including diphtheria, tetanus, pertussis, rubella, and hepatitis B [<xref rid="B135-molecules-26-06057" ref-type="bibr">135</xref>]. In addition to improving life quality it also saves the society for huge expenses to health care. An outstanding example is the present COVID-19 pandemic. Populations with high immunity because of vaccination carry a much smaller burden than poorly vaccinated populations. Since no person can be vaccinated against all infectious diseases antibiotic drugs always will be an important armamentarium in medicine.</p><p>In the fight against malaria, another severe burden for mankind [<xref rid="B26-molecules-26-06057" ref-type="bibr">26</xref>], the assumption that man may defeat Nature turned out to be naive. This also is true for the fight against infectious diseases. Nature always fights back. That is why Nature has become so elaborate. The challenge is continuously to develop innovative drugs that keep the pressure from pathogenic organisms at a minimum, even though the return of investment might be poor. Governmental and international institutions and academia have to develop programs to control the spreading of extended spectrum resistance bacteria.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-26-06057"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Koefoed</surname><given-names>M.</given-names></name>
</person-group><source>Befolkningsforholdene i Danmark</source><publisher-name>Statens Stistiske Buerau</publisher-name><publisher-loc>Copenhagen, Denmark</publisher-loc><year>1905</year></element-citation></ref><ref id="B2-molecules-26-06057"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>G.</given-names></name>
</person-group><source>D&#x000f8;den Skifter &#x000c5;rsag</source><publisher-name>Dansk Sygeplejehistoriske Museum</publisher-name><publisher-loc>Copenhagen, Denmark</publisher-loc><year>2017</year><fpage>15</fpage></element-citation></ref><ref id="B3-molecules-26-06057"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Singer</surname><given-names>C.</given-names></name>
<name><surname>Underwood</surname><given-names>E.A.</given-names></name>
</person-group><source>A Short History of Medicine</source><edition>2nd ed.</edition><publisher-name>Clarendon Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>1962</year></element-citation></ref><ref id="B4-molecules-26-06057"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slavkin</surname><given-names>H.C.</given-names></name>
</person-group><article-title>Biofilms, microbial ecology and Antoni van Leeuwenhoek</article-title><source>J. Am. Dent. Assoc.</source><year>1997</year><volume>128</volume><fpage>492</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.14219/jada.archive.1997.0238</pub-id><?supplied-pmid 9103803?><pub-id pub-id-type="pmid">9103803</pub-id></element-citation></ref><ref id="B5-molecules-26-06057"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>M&#x000fc;ller</surname><given-names>O.F.</given-names></name>
</person-group><source>Animalcula Infusoria Fluviatilia er Marina</source><person-group person-group-type="editor">
<name><surname>M&#x000f6;lleri</surname><given-names>T.N.</given-names></name>
</person-group><publisher-name>Hauni&#x000e6;</publisher-name><publisher-loc>Copenhagen, Denmark</publisher-loc><year>1786</year></element-citation></ref><ref id="B6-molecules-26-06057"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Pasteur</surname><given-names>L.</given-names></name>
</person-group><source>&#x000c9;tude sur le Vin</source><edition>2nd ed.</edition><publisher-name>Librairie F. Savy</publisher-name><publisher-loc>Paris, France</publisher-loc><year>1873</year></element-citation></ref><ref id="B7-molecules-26-06057"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warren</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Unidentified curved bacilli on gastric epithelium in active chronic gastritis</article-title><source>Lancet</source><year>1983</year><volume>1</volume><fpage>1273</fpage><?supplied-pmid 6134060?><pub-id pub-id-type="pmid">6134060</pub-id></element-citation></ref><ref id="B8-molecules-26-06057"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>B.</given-names></name>
</person-group><article-title>Unidentified curved bacilli on gastric epithelium in active chronic gastritis</article-title><source>Lancet</source><year>1983</year><volume>1</volume><fpage>1273</fpage><lpage>1275</lpage><pub-id pub-id-type="pmid">6134060</pub-id></element-citation></ref><ref id="B9-molecules-26-06057"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>B.J.</given-names></name>
<name><surname>Warren</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration</article-title><source>Lancet</source><year>1984</year><volume>1</volume><fpage>1311</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(84)91816-6</pub-id><pub-id pub-id-type="pmid">6145023</pub-id></element-citation></ref><ref id="B10-molecules-26-06057"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciacci</surname><given-names>C.</given-names></name>
<name><surname>Mazzacca</surname><given-names>G.</given-names></name>
</person-group><article-title>The history of <italic toggle="yes">Helicobacter pylori</italic>: A reflection on the relationship between the medical community and industry</article-title><source>Dig. Liver Dis.</source><year>2006</year><volume>38</volume><fpage>778</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2006.06.013</pub-id><pub-id pub-id-type="pmid">16870518</pub-id></element-citation></ref><ref id="B11-molecules-26-06057"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>L.H.</given-names></name>
<name><surname>Latham</surname><given-names>S.M.</given-names></name>
<name><surname>Woolhouse</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Risk factors for human disease emergence</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2001</year><volume>356</volume><fpage>983</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1098/rstb.2001.0888</pub-id><?supplied-pmid 11516376?><pub-id pub-id-type="pmid">11516376</pub-id></element-citation></ref><ref id="B12-molecules-26-06057"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sigerist</surname><given-names>H.E.</given-names></name>
</person-group><article-title>The philosphy of hygiene</article-title><source>Bull. Inst. Hist. Med.</source><year>1933</year><volume>1</volume><fpage>323</fpage><lpage>331</lpage></element-citation></ref><ref id="B13-molecules-26-06057"><label>13.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Abell&#x000e1;n</surname><given-names>J.</given-names></name>
</person-group><article-title>Water supply and sanitation services in modern Europe: Developments in 19th&#x02013;20th centuries</article-title><source>Proceedings of the XII International Congress of the Spanish Associations of Ecnonomic History</source><conf-loc>Salamanaca, Spain</conf-loc><conf-date>2&#x02013;3 February 2017</conf-date><publisher-name>University of Salamanaca</publisher-name><publisher-loc>Salamanaca, Spain</publisher-loc><year>2017</year><fpage>1</fpage><lpage>17</lpage></element-citation></ref><ref id="B14-molecules-26-06057"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khalifa</surname><given-names>M.</given-names></name>
<name><surname>Bidaisee</surname><given-names>S.</given-names></name>
</person-group><article-title>The Importance of Clean Water</article-title><source>Sch. J. Appl. Sci. Res.</source><year>2018</year><volume>1</volume><fpage>17</fpage><lpage>20</lpage></element-citation></ref><ref id="B15-molecules-26-06057"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atanasov</surname><given-names>A.G.</given-names></name>
<name><surname>Zotchev</surname><given-names>S.B.</given-names></name>
<name><surname>Dirsch</surname><given-names>V.M.</given-names></name>
<name><surname>Supuran</surname><given-names>C.</given-names></name>
<collab>The International Natural Product Sciences Taskforce</collab>
</person-group><article-title>Natural products in drug discovery: Advances and opportunities</article-title><source>Nat. Rev. Drug Discovery</source><year>2021</year><volume>20</volume><fpage>200</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-00114-z</pub-id><pub-id pub-id-type="pmid">33510482</pub-id></element-citation></ref><ref id="B16-molecules-26-06057"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porras</surname><given-names>G.</given-names></name>
<name><surname>Chassagne</surname><given-names>F.</given-names></name>
<name><surname>Lyles</surname><given-names>J.T.</given-names></name>
<name><surname>Marquez</surname><given-names>L.</given-names></name>
<name><surname>Dettweiler</surname><given-names>M.</given-names></name>
<name><surname>Salam</surname><given-names>A.M.</given-names></name>
<name><surname>Samarakoon</surname><given-names>T.</given-names></name>
<name><surname>Shabih</surname><given-names>S.</given-names></name>
<name><surname>Farrokhi</surname><given-names>D.R.</given-names></name>
<name><surname>Quave</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Ethnobotany and the Role of Plant Natural Products in Antibiotic Drug Discovery</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><fpage>3495</fpage><lpage>3560</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c00922</pub-id><pub-id pub-id-type="pmid">33164487</pub-id></element-citation></ref><ref id="B17-molecules-26-06057"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>D.J.</given-names></name>
<name><surname>Cragg</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019</article-title><source>J. Nat. Prod.</source><year>2020</year><volume>83</volume><fpage>770</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b01285</pub-id><pub-id pub-id-type="pmid">32162523</pub-id></element-citation></ref><ref id="B18-molecules-26-06057"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riethmiller</surname><given-names>S.</given-names></name>
</person-group><article-title>From Atoxyl to Salvarsan: Searching for the magic bullet</article-title><source>Chemotherapy</source><year>2005</year><volume>51</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1159/000087453</pub-id><pub-id pub-id-type="pmid">16103665</pub-id></element-citation></ref><ref id="B19-molecules-26-06057"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waksman</surname><given-names>S.A.</given-names></name>
</person-group><article-title>What is an antibiotic or an antibiotic substance?</article-title><source>Mycologia</source><year>1947</year><volume>39</volume><fpage>565</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.2307/3755196</pub-id><pub-id pub-id-type="pmid">20264541</pub-id></element-citation></ref><ref id="B20-molecules-26-06057"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Watkins</surname><given-names>W.J.</given-names></name>
<name><surname>Plattner</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Anti-infective drugs through medicinal chemistry: A 50-year retrospective</article-title><source>2015 Medicinal Chemistry Reviews</source><person-group person-group-type="editor">
<name><surname>Desai</surname><given-names>M.C.</given-names></name>
</person-group><publisher-name>American Chemical Society</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2015</year><volume>Volume 50</volume><fpage>242</fpage><lpage>282</lpage></element-citation></ref><ref id="B21-molecules-26-06057"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bassetti</surname><given-names>M.</given-names></name>
<name><surname>Poulakou</surname><given-names>G.</given-names></name>
<name><surname>Ruppe</surname><given-names>E.</given-names></name>
<name><surname>Bouza</surname><given-names>E.</given-names></name>
<name><surname>Van Hal</surname><given-names>S.J.</given-names></name>
<name><surname>Brink</surname><given-names>A.</given-names></name>
</person-group><article-title>Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: A visionary approach</article-title><source>Intensive Care Med.</source><year>2017</year><volume>43</volume><fpage>1464</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.1007/s00134-017-4878-x</pub-id><pub-id pub-id-type="pmid">28733718</pub-id></element-citation></ref><ref id="B22-molecules-26-06057"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Marko</surname><given-names>V.</given-names></name>
</person-group><source>From Aspitin to Viagara</source><publisher-name>Springer Nature</publisher-name><publisher-loc>Cham, Schwitzerland</publisher-loc><year>2020</year></element-citation></ref><ref id="B23-molecules-26-06057"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Report of a series of cases of syphilis terated by Ehrlich&#x02019;s arsenobenzol at the Walter Reed General Hospital Distict of Columbia</article-title><source>Boston Med. Surg. J.</source><year>1911</year><volume>164</volume><fpage>381</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1056/NEJM191103161641103</pub-id></element-citation></ref><ref id="B24-molecules-26-06057"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lloyd</surname><given-names>N.C.</given-names></name>
<name><surname>Morgan</surname><given-names>H.W.</given-names></name>
<name><surname>Nicholson</surname><given-names>B.K.</given-names></name>
<name><surname>Ronimus</surname><given-names>R.S.</given-names></name>
</person-group><article-title>The composition of Ehrlich&#x02019;s salvarsan: Resolution of a century-old debate</article-title><source>Angew. Chem. Int. Ed.</source><year>2005</year><volume>44</volume><fpage>941</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1002/anie.200461471</pub-id></element-citation></ref><ref id="B25-molecules-26-06057"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Perspective: Paul Ehrlich&#x02019;s magic bullets</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>1079</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1056/NEJMp048021</pub-id><pub-id pub-id-type="pmid">15014180</pub-id></element-citation></ref><ref id="B26-molecules-26-06057"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Natrual Products that Changed Society</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><elocation-id>472</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines9050472</pub-id><pub-id pub-id-type="pmid">33925870</pub-id></element-citation></ref><ref id="B27-molecules-26-06057"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Lesch</surname><given-names>J.E.</given-names></name>
</person-group><source>The First Miracle Drugs. How the Sulfa Drugs Transformed Medicine</source><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2007</year></element-citation></ref><ref id="B28-molecules-26-06057"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Domagk</surname><given-names>G.</given-names></name>
</person-group><article-title>Ein Beitrag zur Chemotherapie der bakteriellen Infektionen</article-title><source>Dtsch. Med. Wochenschr.</source><year>1935</year><volume>61</volume><fpage>250</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1129486</pub-id></element-citation></ref><ref id="B29-molecules-26-06057"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klee</surname><given-names>P.H.</given-names></name>
<name><surname>R&#x000f6;mer</surname><given-names>H.</given-names></name>
</person-group><article-title>Pontosil bei Streptokokkenkrankungen</article-title><source>Dtsch. Med. Wochenschr.</source><year>1935</year><volume>61</volume><fpage>253</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1129487</pub-id></element-citation></ref><ref id="B30-molecules-26-06057"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>H.</given-names></name>
</person-group><article-title>The last year before the dawn of antibiotics</article-title><source>Br. J. Hosp. Med.</source><year>2009</year><volume>70</volume><fpage>475</fpage><pub-id pub-id-type="doi">10.12968/hmed.2009.70.8.43543</pub-id><?supplied-pmid 19684540?><pub-id pub-id-type="pmid">19684540</pub-id></element-citation></ref><ref id="B31-molecules-26-06057"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trefouel</surname><given-names>J.</given-names></name>
<name><surname>Nitti</surname><given-names>F.</given-names></name>
<name><surname>Bovet</surname><given-names>D.</given-names></name>
</person-group><article-title>Activit&#x000e9; du p-aminoph&#x000e9;nylsulfamide sur les infecti&#x000f3;ns streptococciques enxp&#x000e9;rimentales de la souris du lapin</article-title><source>C. R. Seances Soc. Biol. Ses. Fil.</source><year>1935</year><volume>120</volume><fpage>756</fpage><lpage>758</lpage></element-citation></ref><ref id="B32-molecules-26-06057"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colebrook</surname><given-names>L.</given-names></name>
<name><surname>Buttle</surname><given-names>G.A.H.</given-names></name>
<name><surname>O&#x02019;Meara</surname><given-names>R.A.Q.</given-names></name>
</person-group><article-title>The mode of action of p-aminobenzenesulfonamide and Prontosil in h&#x000e6;molytic streptococcal infections</article-title><source>Lancet</source><year>1936</year><volume>228</volume><fpage>1323</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)48181-X</pub-id></element-citation></ref><ref id="B33-molecules-26-06057"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuller</surname><given-names>A.T.</given-names></name>
</person-group><article-title>Is p-aminobenzenesulphonamide the active agent in prontosil therapy?</article-title><source>Lancet</source><year>1937</year><volume>229</volume><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)97447-6</pub-id></element-citation></ref><ref id="B34-molecules-26-06057"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Loudon</surname><given-names>I.</given-names></name>
</person-group><article-title>Maternal Care and Maternal Mortality in Britain, 1935&#x02013;1950</article-title><source>Death in Childbirth: An International Study of Maternal Care and Maternal Mortality 1800&#x02013;1950</source><person-group person-group-type="editor">
<name><surname>Loudon</surname><given-names>I.</given-names></name>
</person-group><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>1992</year><fpage>255</fpage><lpage>270</lpage></element-citation></ref><ref id="B35-molecules-26-06057"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fildes</surname><given-names>P.</given-names></name>
</person-group><article-title>A rational approach to research in chemotherapy</article-title><source>Lancet</source><year>1940</year><volume>238</volume><fpage>955</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)72741-3</pub-id></element-citation></ref><ref id="B36-molecules-26-06057"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azevedo-Barbosa</surname><given-names>H.</given-names></name>
<name><surname>Dias</surname><given-names>D.F.</given-names></name>
<name><surname>Franco</surname><given-names>L.L.</given-names></name>
<name><surname>Hawkes</surname><given-names>J.A.</given-names></name>
<name><surname>Carvalho</surname><given-names>D.T.</given-names></name>
</person-group><article-title>From Antibacterial to Antitumour Agents: A Brief Review on The Chemical and Medicinal Aspects of Sulfonamides</article-title><source>Mini-Rev. Med. Chem.</source><year>2020</year><volume>20</volume><fpage>2052</fpage><lpage>2066</lpage><pub-id pub-id-type="doi">10.2174/1389557520666200905125738</pub-id><pub-id pub-id-type="pmid">32888265</pub-id></element-citation></ref><ref id="B37-molecules-26-06057"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Dewick</surname><given-names>P.M.</given-names></name>
</person-group><source>Medicinal Natural Products</source><edition>3rd ed.</edition><publisher-name>John Wiley and Sons Ltd.</publisher-name><publisher-loc>Chicester, UK</publisher-loc><year>2009</year></element-citation></ref><ref id="B38-molecules-26-06057"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lima</surname><given-names>L.M.</given-names></name>
<name><surname>Silva</surname><given-names>B.N.M.d.</given-names></name>
<name><surname>Barbosa</surname><given-names>G.</given-names></name>
<name><surname>Barreiro</surname><given-names>E.J.</given-names></name>
</person-group><article-title>&#x003b2;-Lactam antibiotics: An overview from a medicinal chemistry perspective</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>208</volume><fpage>112829</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112829</pub-id><pub-id pub-id-type="pmid">33002736</pub-id></element-citation></ref><ref id="B39-molecules-26-06057"><label>39.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Palavecino</surname><given-names>E.L.</given-names></name>
</person-group><article-title>Clinical, Epidemiologic, and Laboratory Aspects of Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Infections. Cutting-Edge Technologies and Advancements</article-title><source>Methicillin-Resistant Staphylococcus aureus (MRSA) Protocols</source><edition>3rd ed.</edition><person-group person-group-type="editor">
<name><surname>Ji</surname><given-names>Y.</given-names></name>
</person-group><publisher-name>Humana Press</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2020</year><fpage>1</fpage><lpage>28</lpage></element-citation></ref><ref id="B40-molecules-26-06057"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fleming</surname><given-names>A.</given-names></name>
</person-group><article-title>The antibacterial action of cultures of a <italic toggle="yes">Penicillium</italic>, with special reference to their use in the isolation of <italic toggle="yes">B. influenz&#x000e6;</italic></article-title><source>Br. J. Exp. Pathol.</source><year>1929</year><volume>10</volume><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1093/clinids/2.1.129</pub-id></element-citation></ref><ref id="B41-molecules-26-06057"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaffiri</surname><given-names>L.</given-names></name>
<name><surname>Gardner</surname><given-names>J.</given-names></name>
<name><surname>Toledo-Pereyra</surname><given-names>L.H.</given-names></name>
</person-group><article-title>History of antibiotics. From salvarsan to cephalosporins</article-title><source>J. Investig. Surg.</source><year>2012</year><volume>25</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.3109/08941939.2012.664099</pub-id><pub-id pub-id-type="pmid">22439833</pub-id></element-citation></ref><ref id="B42-molecules-26-06057"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nayler</surname><given-names>J.H.C.</given-names></name>
</person-group><article-title>Early discoveries in the penicillin series</article-title><source>Trends Biochem. Sci.</source><year>1991</year><volume>16</volume><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/0968-0004(91)90076-8</pub-id><pub-id pub-id-type="pmid">1652802</pub-id></element-citation></ref><ref id="B43-molecules-26-06057"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Petri</surname><given-names>W.A.</given-names></name>
</person-group><article-title>Penicillins, cephalosporins, and other beta-lactam antibiotics</article-title><source>Goodman &#x00026; Gilman&#x02019;s the Pharmacological Basis of Therapeutics</source><edition>12th ed.</edition><person-group person-group-type="editor">
<name><surname>Brunton</surname><given-names>L.L.</given-names></name>
</person-group><publisher-name>McGraw Hill Medicinal</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2011</year><fpage>1477</fpage><lpage>1504</lpage></element-citation></ref><ref id="B44-molecules-26-06057"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Burton</surname><given-names>G.</given-names></name>
<name><surname>Osborne</surname><given-names>N.F.</given-names></name>
<name><surname>Pearson</surname><given-names>M.</given-names></name>
<name><surname>Southgate</surname><given-names>R.</given-names></name>
</person-group><article-title>The b-Lactam Antibiotics</article-title><source>Burger&#x02019;s Medicinal Chemistry and Drug Discovery</source><person-group person-group-type="editor">
<name><surname>Wolff</surname><given-names>M.E.</given-names></name>
</person-group><publisher-name>John Wiley &#x00026; Sons</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>1997</year><volume>Volume 4</volume><fpage>277</fpage><lpage>363</lpage></element-citation></ref><ref id="B45-molecules-26-06057"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pitts</surname><given-names>C.R.</given-names></name>
<name><surname>Lectka</surname><given-names>T.</given-names></name>
</person-group><article-title>Chemical Synthesis of &#x003b2;-Lactams: Asymmetric Catalysis and Other Recent Advances</article-title><source>Chem. Rev.</source><year>2014</year><volume>114</volume><fpage>7930</fpage><lpage>7953</lpage><pub-id pub-id-type="doi">10.1021/cr4005549</pub-id><pub-id pub-id-type="pmid">24555548</pub-id></element-citation></ref><ref id="B46-molecules-26-06057"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schr&#x000f8;der</surname><given-names>P.</given-names></name>
</person-group><article-title>Fra L&#x000f8;vens Kemiske Fabrik til Leo Pharma A/S</article-title><source>Theriaca</source><year>2005</year><volume>36</volume><fpage>27</fpage><lpage>118</lpage></element-citation></ref><ref id="B47-molecules-26-06057"><label>47.</label><element-citation publication-type="journal"><article-title>Chemistry of Penicilin</article-title><source>Nature</source><year>1945</year><volume>156</volume><fpage>766</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1038/156766a0</pub-id></element-citation></ref><ref id="B48-molecules-26-06057"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Council T.C.o.M.R.a.T.M.R.</collab>
</person-group><article-title>Chemistry of Penicillin</article-title><source>Science</source><year>1945</year><volume>102</volume><fpage>627</fpage><lpage>629</lpage></element-citation></ref><ref id="B49-molecules-26-06057"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nicolaou</surname><given-names>K.C.</given-names></name>
<name><surname>Snyder</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Chasing molecules that were never there: Misassigned natural products and the role of chemical synthesis in modern structure elucidation</article-title><source>Angew. Chem. Int. Ed.</source><year>2005</year><volume>44</volume><fpage>1012</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1002/anie.200460864</pub-id></element-citation></ref><ref id="B50-molecules-26-06057"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hodgkin</surname><given-names>D.C.</given-names></name>
</person-group><article-title>X-ray analysis of the structure of penicillin</article-title><source>Adv. Sci.</source><year>1949</year><volume>6</volume><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">18134678</pub-id></element-citation></ref><ref id="B51-molecules-26-06057"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woodward</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Penems and related substances</article-title><source>Philos. Trans. R. Soc. Lond. Ser. B</source><year>1980</year><volume>289</volume><fpage>239</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">6109320</pub-id></element-citation></ref><ref id="B52-molecules-26-06057"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>J.F.</given-names></name>
<name><surname>Mobashery</surname><given-names>S.</given-names></name>
</person-group><article-title>b-Lactams against the Fortress of the Gram-Positive Staphylococcus aureus Bacterium</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><fpage>3412</fpage><lpage>3463</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c01010</pub-id><pub-id pub-id-type="pmid">33373523</pub-id></element-citation></ref><ref id="B53-molecules-26-06057"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>M.</given-names></name>
<name><surname>Pyle</surname><given-names>D.J.</given-names></name>
<name><surname>Bisz</surname><given-names>E.</given-names></name>
<name><surname>Dziuk</surname><given-names>B.</given-names></name>
<name><surname>Ejsmont</surname><given-names>K.</given-names></name>
<name><surname>Lalancette</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Szostak</surname><given-names>R.</given-names></name>
<name><surname>Szostak</surname><given-names>M.</given-names></name>
</person-group><article-title>Evaluation of Cyclic Amides as Activating Groups in N&#x02212;C Bond Cross-Coupling: Discovery of N-Acyl-&#x003b4;-valerolactams as Effective Twisted Amide Precursors for Cross-Coupling Reactions</article-title><source>J. Org. Chem.</source><year>2021</year><volume>86</volume><fpage>10455</fpage><lpage>10466</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.1c01110</pub-id><pub-id pub-id-type="pmid">34275281</pub-id></element-citation></ref><ref id="B54-molecules-26-06057"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lejon</surname><given-names>S.</given-names></name>
<name><surname>Ellis</surname><given-names>J.</given-names></name>
<name><surname>Valegard</surname><given-names>K.</given-names></name>
</person-group><article-title>The Last Step in Cephalosporin C Formation Revealed: Crystal Structures of Deacetylcephalosporin C Acetyltransferase from <italic toggle="yes">Acremonium chrysogenum</italic> in Complexes with Reaction Intermediates</article-title><source>J. Mol. Biol.</source><year>2008</year><volume>377</volume><fpage>935</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2008.01.047</pub-id><pub-id pub-id-type="pmid">18279889</pub-id></element-citation></ref><ref id="B55-molecules-26-06057"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rolinson</surname><given-names>G.N.</given-names></name>
</person-group><article-title>Forty years of &#x003b2;-lactam research</article-title><source>J. Antimicrob. Chemother.</source><year>1998</year><volume>41</volume><fpage>589</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1093/jac/41.6.589</pub-id><?supplied-pmid 9687097?><pub-id pub-id-type="pmid">9687097</pub-id></element-citation></ref><ref id="B56-molecules-26-06057"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Batchelor</surname><given-names>F.R.</given-names></name>
<name><surname>Doyle</surname><given-names>F.P.</given-names></name>
<name><surname>Nayler</surname><given-names>J.H.C.</given-names></name>
<name><surname>Rolinson</surname><given-names>G.N.</given-names></name>
</person-group><article-title>Synthesis of penicillin-6-aminopenicillanic acid in penicillin fermentations</article-title><source>Nature</source><year>1959</year><volume>183</volume><fpage>257</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/183257b0</pub-id><?supplied-pmid 13622762?><pub-id pub-id-type="pmid">13622762</pub-id></element-citation></ref><ref id="B57-molecules-26-06057"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nayler</surname><given-names>J.H.C.</given-names></name>
</person-group><article-title>Semi-synthetic approaches to novel penicillins</article-title><source>Trends Biochem. Sci.</source><year>1991</year><volume>16</volume><fpage>234</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/0968-0004(91)90092-A</pub-id><pub-id pub-id-type="pmid">1891804</pub-id></element-citation></ref><ref id="B58-molecules-26-06057"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>D.Y.</given-names></name>
<name><surname>Abboud</surname><given-names>M.I.</given-names></name>
<name><surname>Markoulides</surname><given-names>M.S.</given-names></name>
<name><surname>Brem</surname><given-names>J.</given-names></name>
<name><surname>Schofield</surname><given-names>C.J.</given-names></name>
</person-group><article-title>The road to avibactam: The first clinically useful non-&#x003b2;-lactam working somewhat like a &#x003b2;-lactam</article-title><source>Future Med. Chem.</source><year>2016</year><volume>8</volume><fpage>1063</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.4155/fmc-2016-0078</pub-id><pub-id pub-id-type="pmid">27327972</pub-id></element-citation></ref><ref id="B59-molecules-26-06057"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tipper</surname><given-names>D.J.</given-names></name>
<name><surname>Strominger</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Mechanism of action of penicillins; a proposal based on their structural similarity to acyl-D-alanyl-D-alanine</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1965</year><volume>54</volume><fpage>1133</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1073/pnas.54.4.1133</pub-id><pub-id pub-id-type="pmid">5219821</pub-id></element-citation></ref><ref id="B60-molecules-26-06057"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliva</surname><given-names>M.</given-names></name>
<name><surname>Dideberg</surname><given-names>O.</given-names></name>
<name><surname>Field</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Understanding the acylation mechanisms of active-site serine penicillin-recognizing proteins: A molecular dynamics simulation study</article-title><source>Proteins Struct. Funct. Genet.</source><year>2003</year><volume>53</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1002/prot.10450</pub-id><pub-id pub-id-type="pmid">12945052</pub-id></element-citation></ref><ref id="B61-molecules-26-06057"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boehme</surname><given-names>E.H.W.</given-names></name>
<name><surname>Applegate</surname><given-names>H.E.</given-names></name>
<name><surname>Toeplitz</surname><given-names>B.</given-names></name>
<name><surname>Dolfini</surname><given-names>J.E.</given-names></name>
<name><surname>Gougoutas</surname><given-names>J.Z.</given-names></name>
</person-group><article-title>6-Methyl penicillins and 7-methyl cephalosporins</article-title><source>J. Amer. Chem. Soc.</source><year>1971</year><volume>93</volume><fpage>4324</fpage><lpage>4326</lpage><pub-id pub-id-type="doi">10.1021/ja00746a057</pub-id><pub-id pub-id-type="pmid">5131150</pub-id></element-citation></ref><ref id="B62-molecules-26-06057"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakaguchi</surname><given-names>K.i.</given-names></name>
<name><surname>Murao</surname><given-names>S.</given-names></name>
</person-group><article-title>A new enzyme, penicillin-amidase. Preliminary</article-title><source>Nippon Nogei Kagaku Kaishi</source><year>1950</year><volume>23</volume><fpage>411</fpage><pub-id pub-id-type="doi">10.1271/nogeikagaku1924.23.411</pub-id></element-citation></ref><ref id="B63-molecules-26-06057"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williamson</surname><given-names>G.M.</given-names></name>
<name><surname>Morrison</surname><given-names>J.K.</given-names></name>
<name><surname>Stevens</surname><given-names>K.J.</given-names></name>
</person-group><article-title>A new synthetic penicillin PA-248</article-title><source>Lancet</source><year>1961</year><volume>1</volume><fpage>847</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(61)90174-X</pub-id><pub-id pub-id-type="pmid">13785541</pub-id></element-citation></ref><ref id="B64-molecules-26-06057"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagley</surname><given-names>M.</given-names></name>
</person-group><article-title>Clinical use of a new synthetic penicillin: PA-248</article-title><source>Lancet</source><year>1961</year><volume>1</volume><fpage>851</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(61)90176-3</pub-id><pub-id pub-id-type="pmid">13727457</pub-id></element-citation></ref><ref id="B65-molecules-26-06057"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peter</surname><given-names>G.</given-names></name>
</person-group><article-title>Streptococcal pharyngitis: Current therapy and criteria for evaluation of new agents</article-title><source>Clin. Infect. Dis.</source><year>1992</year><volume>14</volume><issue>(Suppl. S2)</issue><fpage>S218</fpage><lpage>S223</lpage><pub-id pub-id-type="doi">10.1093/clinids/14.Supplement_2.S218</pub-id><pub-id pub-id-type="pmid">1617041</pub-id></element-citation></ref><ref id="B66-molecules-26-06057"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischbach</surname><given-names>M.A.</given-names></name>
<name><surname>Walsh</surname><given-names>C.T.</given-names></name>
</person-group><article-title>Antibiotics for Emerging Pathogens</article-title><source>Science</source><year>2009</year><volume>325</volume><fpage>1089</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1126/science.1176667</pub-id><pub-id pub-id-type="pmid">19713519</pub-id></element-citation></ref><ref id="B67-molecules-26-06057"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rolinson</surname><given-names>G.N.</given-names></name>
<name><surname>Geddes</surname><given-names>A.M.</given-names></name>
</person-group><article-title>The 50th anniversary of the discovery of 6-aminopenicillanic acid (6-APA)</article-title><source>Int. J. Antimicrob. Agents</source><year>2007</year><volume>29</volume><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2006.09.003</pub-id><pub-id pub-id-type="pmid">17137753</pub-id></element-citation></ref><ref id="B68-molecules-26-06057"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikaido</surname><given-names>H.</given-names></name>
</person-group><article-title>Antibiotic resistance caused by Gram-negative multidrug efflux pumps</article-title><source>Clin. Infect. Dis.</source><year>1998</year><volume>27</volume><issue>(Suppl. S1)</issue><fpage>S32</fpage><lpage>S41</lpage><pub-id pub-id-type="doi">10.1086/514920</pub-id><pub-id pub-id-type="pmid">9710669</pub-id></element-citation></ref><ref id="B69-molecules-26-06057"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>E.P.</given-names></name>
<name><surname>Chain</surname><given-names>E.</given-names></name>
</person-group><article-title>An enzyme from bacteria able to destroy penicillin</article-title><source>Nature</source><year>1940</year><volume>146</volume><fpage>837</fpage><pub-id pub-id-type="doi">10.1038/146837a0</pub-id></element-citation></ref><ref id="B70-molecules-26-06057"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogawara</surname><given-names>H.</given-names></name>
</person-group><article-title>Self-resistance in <italic toggle="yes">Streptomyces</italic>, with special reference to &#x003b2;-lactam antibiotics</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>605</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21050605</pub-id></element-citation></ref><ref id="B71-molecules-26-06057"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>E.S.</given-names></name>
<name><surname>Datta</surname><given-names>N.</given-names></name>
</person-group><article-title>Resistance to Penicillins and its transfer in enterobacteriaceae</article-title><source>Lancet</source><year>1965</year><volume>1</volume><fpage>407</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(65)90004-8</pub-id><pub-id pub-id-type="pmid">14238093</pub-id></element-citation></ref><ref id="B72-molecules-26-06057"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Qin</surname><given-names>W.</given-names></name>
<name><surname>Wu</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
</person-group><article-title>Fluorogenic Probes/Inhibitors of &#x003b2;-Lactamase and their Applications in Drug-Resistant Bacteria</article-title><source>Angew. Chem. Int. Ed.</source><year>2021</year><volume>60</volume><fpage>24</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/anie.202006635</pub-id></element-citation></ref><ref id="B73-molecules-26-06057"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x02019;Costa</surname><given-names>V.M.</given-names></name>
<name><surname>King</surname><given-names>C.E.</given-names></name>
<name><surname>Kalan</surname><given-names>L.</given-names></name>
<name><surname>Morar</surname><given-names>M.</given-names></name>
<name><surname>Sung</surname><given-names>W.W.L.</given-names></name>
<name><surname>Schwarz</surname><given-names>C.</given-names></name>
<name><surname>Froese</surname><given-names>D.</given-names></name>
<name><surname>Zazula</surname><given-names>G.</given-names></name>
<name><surname>Calmels</surname><given-names>F.</given-names></name>
<name><surname>Debruyne</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Antibiotic resistance is ancient</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>457</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1038/nature10388</pub-id><pub-id pub-id-type="pmid">21881561</pub-id></element-citation></ref><ref id="B74-molecules-26-06057"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ambler</surname><given-names>R.P.</given-names></name>
</person-group><article-title>The structure of &#x003b2;-lactamases</article-title><source>Philos. Trans. R. Soc. Lond. Ser. B</source><year>1980</year><volume>289</volume><fpage>321</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">6109327</pub-id></element-citation></ref><ref id="B75-molecules-26-06057"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Datta</surname><given-names>N.</given-names></name>
<name><surname>Kontomichalou</surname><given-names>P.</given-names></name>
</person-group><article-title>Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae</article-title><source>Nature</source><year>1965</year><volume>208</volume><fpage>239</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1038/208239a0</pub-id><?supplied-pmid 5326330?><pub-id pub-id-type="pmid">5326330</pub-id></element-citation></ref><ref id="B76-molecules-26-06057"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cullmann</surname><given-names>W.</given-names></name>
<name><surname>Dick</surname><given-names>W.</given-names></name>
</person-group><article-title>Induction potency of various beta-lactam derivatives in gram-negative rods</article-title><source>Chemotherapy</source><year>1989</year><volume>35</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1159/000238634</pub-id><?supplied-pmid 2785904?><pub-id pub-id-type="pmid">2785904</pub-id></element-citation></ref><ref id="B77-molecules-26-06057"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davies</surname><given-names>D.T.</given-names></name>
<name><surname>Everett</surname><given-names>M.</given-names></name>
</person-group><article-title>Designing Inhibitors of &#x003b2;-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria</article-title><source>Acc. Chem. Res.</source><year>2021</year><volume>54</volume><fpage>2055</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.0c00863</pub-id><?supplied-pmid 33788541?><pub-id pub-id-type="pmid">33788541</pub-id></element-citation></ref><ref id="B78-molecules-26-06057"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Araujo Viana Marques</surname><given-names>D.</given-names></name>
<name><surname>Machado</surname><given-names>S.E.F.</given-names></name>
<name><surname>Ebinuma</surname><given-names>V.C.S.</given-names></name>
<name><surname>de Albuquerque Lima Duarte</surname><given-names>C.</given-names></name>
<name><surname>Converti</surname><given-names>A.</given-names></name>
<name><surname>Porto</surname><given-names>A.L.F.</given-names></name>
</person-group><article-title>Production of &#x003b2;-lactamase inhibitors by <italic toggle="yes">Streptomyces</italic> species</article-title><source>Antibiotics</source><year>2018</year><volume>7</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics7030061</pub-id></element-citation></ref><ref id="B79-molecules-26-06057"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doyle</surname><given-names>F.P.</given-names></name>
<name><surname>Hardy</surname><given-names>K.</given-names></name>
<name><surname>Nayler</surname><given-names>J.H.C.</given-names></name>
<name><surname>Soulal</surname><given-names>M.J.</given-names></name>
<name><surname>Stove</surname><given-names>E.R.</given-names></name>
<name><surname>Waddington</surname><given-names>H.R.J.</given-names></name>
</person-group><article-title>Derivatives of 6-aminopenicillanic acid. III. 2,6-Dialkoxybenzoyl derivatives</article-title><source>J. Chem. Soc.</source><year>1962</year><fpage>1453</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1039/jr9620001453</pub-id></element-citation></ref><ref id="B80-molecules-26-06057"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moriyama</surname><given-names>Y.</given-names></name>
<name><surname>Ishikane</surname><given-names>M.</given-names></name>
<name><surname>Mezaki</surname><given-names>K.</given-names></name>
<name><surname>Ohmagari</surname><given-names>N.</given-names></name>
</person-group><article-title>Comparison of penicillins (penicillin G and ampicillin) and cefazolin as a definitive therapy against penicillin-susceptible Staphylococcus aureus (PSSA) bacteremia in Japan: A retrospective cohort study</article-title><source>J. Infect. Chemother.</source><year>2020</year><volume>26</volume><fpage>358</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2019.10.023</pub-id><pub-id pub-id-type="pmid">31822451</pub-id></element-citation></ref><ref id="B81-molecules-26-06057"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanders</surname><given-names>C.C.</given-names></name>
<name><surname>Sanders</surname><given-names>W.E.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Beta-Lactam resistance in gram-negative bacteria: Global trends and clinical impact</article-title><source>Clin. Infect. Dis.</source><year>1992</year><volume>15</volume><fpage>824</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1093/clind/15.5.824</pub-id><pub-id pub-id-type="pmid">1445981</pub-id></element-citation></ref><ref id="B82-molecules-26-06057"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baldwin</surname><given-names>J.E.</given-names></name>
<name><surname>Urban</surname><given-names>F.J.</given-names></name>
<name><surname>Cooper</surname><given-names>R.D.</given-names></name>
<name><surname>Jose</surname><given-names>F.L.</given-names></name>
</person-group><article-title>Direct 6-methoxylation of penicillin derivatives. A convenient pathway to substituted -lactam antibiotics</article-title><source>J. Am. Chem. Soc.</source><year>1973</year><volume>95</volume><fpage>2401</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1021/ja00788a071</pub-id><pub-id pub-id-type="pmid">4709241</pub-id></element-citation></ref><ref id="B83-molecules-26-06057"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Basker</surname><given-names>M.J.</given-names></name>
<name><surname>Edmondson</surname><given-names>R.A.</given-names></name>
<name><surname>Knott</surname><given-names>S.J.</given-names></name>
<name><surname>Ponsford</surname><given-names>R.J.</given-names></name>
<name><surname>Slocombe</surname><given-names>B.</given-names></name>
<name><surname>White</surname><given-names>S.J.</given-names></name>
</person-group><article-title>In vitro antibacterial properties of BRL 36650, a novel 6&#x003b1;-substituted penicillin</article-title><source>Antimicrob. Agents Chemother.</source><year>1984</year><volume>26</volume><fpage>734</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1128/AAC.26.5.734</pub-id><pub-id pub-id-type="pmid">6440479</pub-id></element-citation></ref><ref id="B84-molecules-26-06057"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>D.G.</given-names></name>
<name><surname>Wobst</surname><given-names>H.J.</given-names></name>
</person-group><article-title>A Decade of FDA-Approved Drugs (2010&#x02013;2019): Trends and Future Directions</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><fpage>2312</fpage><lpage>2338</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01516</pub-id><pub-id pub-id-type="pmid">33617254</pub-id></element-citation></ref><ref id="B85-molecules-26-06057"><label>85.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Murakami</surname><given-names>M.</given-names></name>
<name><surname>Takahashi</surname><given-names>K.</given-names></name>
<name><surname>Isaka</surname><given-names>I.</given-names></name>
<name><surname>Kawahara</surname><given-names>N.</given-names></name>
<name><surname>Horiguchi</surname><given-names>H.</given-names></name>
<name><surname>Murakami</surname><given-names>Y.</given-names></name>
<name><surname>Sakamoto</surname><given-names>N.</given-names></name>
<name><surname>Ozasa</surname><given-names>T.</given-names></name>
<name><surname>Kashiwagi</surname><given-names>T.</given-names></name>
<name><surname>Nakano</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>New Oxymethylester Derivatives of Penicillin and Cephalosporin</article-title><source>German Patent</source><patent>DE2228670A1</patent><day>11</day><month>January</month><year>1973</year></element-citation></ref><ref id="B86-molecules-26-06057"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roholt</surname><given-names>K.</given-names></name>
<name><surname>Nielsen</surname><given-names>B.</given-names></name>
<name><surname>Kristensen</surname><given-names>E.</given-names></name>
</person-group><article-title>Clinical pharmacology of pivampicillin</article-title><source>Antimicrob. Agents Chemother.</source><year>1974</year><volume>6</volume><fpage>563</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1128/AAC.6.5.563</pub-id><pub-id pub-id-type="pmid">15825306</pub-id></element-citation></ref><ref id="B87-molecules-26-06057"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rose</surname><given-names>S.J.</given-names></name>
<name><surname>Stokes</surname><given-names>T.C.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Cooper</surname><given-names>M.B.</given-names></name>
<name><surname>Betteridge</surname><given-names>D.J.</given-names></name>
<name><surname>Payne</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Carnitine deficiency associated with long-term pivampicillin treatment: The effect of a replacement therapy regime</article-title><source>Postgrad. Med. J.</source><year>1992</year><volume>68</volume><fpage>932</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1136/pgmj.68.805.932</pub-id><pub-id pub-id-type="pmid">1494519</pub-id></element-citation></ref><ref id="B88-molecules-26-06057"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clayton</surname><given-names>J.P.</given-names></name>
<name><surname>Cole</surname><given-names>M.</given-names></name>
<name><surname>Elson</surname><given-names>S.W.</given-names></name>
<name><surname>Ferres</surname><given-names>H.</given-names></name>
</person-group><article-title>BRL.8988 (Talampicillin), a well-absorbed oral form of ampicillin</article-title><source>Antimicrob. Agents Chemother.</source><year>1974</year><volume>5</volume><fpage>670</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1128/AAC.5.6.670</pub-id><pub-id pub-id-type="pmid">15825424</pub-id></element-citation></ref><ref id="B89-molecules-26-06057"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>J.S.</given-names></name>
<name><surname>Salstrom</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Bacampicillin, ampicillin, cephalothin and cephapirin levels in human blood and interstitial fluid</article-title><source>Antimicrob. Agents Chemother.</source><year>1979</year><volume>15</volume><fpage>510</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1128/AAC.15.4.510</pub-id><pub-id pub-id-type="pmid">464583</pub-id></element-citation></ref><ref id="B90-molecules-26-06057"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Omata</surname><given-names>H.</given-names></name>
<name><surname>Komiya</surname><given-names>M.</given-names></name>
<name><surname>Akimoto</surname><given-names>Y.</given-names></name>
<name><surname>Kaneko</surname><given-names>K.</given-names></name>
<name><surname>Fujii</surname><given-names>A.</given-names></name>
</person-group><article-title>Ampicillin concentrations in human serum and oral tissues following a single oral administration of lenampicillin</article-title><source>Chemotherapy</source><year>1994</year><volume>42</volume><fpage>172</fpage><lpage>176</lpage></element-citation></ref><ref id="B91-molecules-26-06057"><label>91.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>E.P.</given-names></name>
<name><surname>Loder</surname><given-names>P.B.</given-names></name>
</person-group><article-title>Cephalosporin C</article-title><source>Cephalosporins and Penicillins</source><person-group person-group-type="editor">
<name><surname>Flynn</surname><given-names>E.H.</given-names></name>
</person-group><publisher-name>Princeton University Press</publisher-name><publisher-loc>London, UK</publisher-loc><year>1972</year><fpage>1</fpage><lpage>26</lpage></element-citation></ref><ref id="B92-molecules-26-06057"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newton</surname><given-names>G.G.F.</given-names></name>
<name><surname>Abraham</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Cephalosporin C, a new antibiotic containing sulfur and D-&#x003b1;-aminoadipic acid</article-title><source>Nature</source><year>1955</year><volume>175</volume><fpage>548</fpage><pub-id pub-id-type="doi">10.1038/175548a0</pub-id><pub-id pub-id-type="pmid">14370161</pub-id></element-citation></ref><ref id="B93-molecules-26-06057"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>E.P.</given-names></name>
<name><surname>Newton</surname><given-names>G.G.F.</given-names></name>
</person-group><article-title>Structure of cephalosporin C</article-title><source>Biochem. J.</source><year>1961</year><volume>79</volume><fpage>377</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1042/bj0790377</pub-id><pub-id pub-id-type="pmid">13681080</pub-id></element-citation></ref><ref id="B94-molecules-26-06057"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hodgkin</surname><given-names>D.C.</given-names></name>
<name><surname>Maslen</surname><given-names>E.N.</given-names></name>
</person-group><article-title>The X-ray analysis of the structure of cephalosporin C</article-title><source>Biochem. J.</source><year>1961</year><volume>79</volume><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1042/bj0790393</pub-id><pub-id pub-id-type="pmid">13714852</pub-id></element-citation></ref><ref id="B95-molecules-26-06057"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morin</surname><given-names>R.B.</given-names></name>
<name><surname>Jackson</surname><given-names>B.G.</given-names></name>
<name><surname>Mueller</surname><given-names>R.A.</given-names></name>
<name><surname>Lavagnino</surname><given-names>E.R.</given-names></name>
<name><surname>Scanlon</surname><given-names>W.B.</given-names></name>
<name><surname>Andrews</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Chemistry of cephalosporin antibiotics. III. Chemical correlation of penicillin and cephalosporin antibiotics</article-title><source>J. Am. Chem. Soc.</source><year>1963</year><volume>85</volume><fpage>1896</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1021/ja00895a063</pub-id></element-citation></ref><ref id="B96-molecules-26-06057"><label>96.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Lucinova</surname><given-names>E.</given-names></name>
<name><surname>Welward</surname><given-names>L.</given-names></name>
<name><surname>Frimm</surname><given-names>R.</given-names></name>
<name><surname>Kosalko</surname><given-names>R.</given-names></name>
<name><surname>Sokol</surname><given-names>M.</given-names></name>
</person-group><article-title>7-Aminocephalosporanic Acid</article-title><source>Czech Patent</source><patent>CS193181B1</patent><day>31</day><month>October</month><year>1979</year></element-citation></ref><ref id="B97-molecules-26-06057"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hardianto</surname><given-names>D.</given-names></name>
<name><surname>Royani</surname><given-names>J.I.</given-names></name>
<name><surname>Safarrida</surname><given-names>A.</given-names></name>
</person-group><article-title>Cephalosporin C acylase from microbes for one-step enzymatic transformation of cephalosporin C to 7-aminocephalosporanic acid</article-title><source>J. Pure Appl. Microbiol.</source><year>2016</year><volume>10</volume><fpage>2495</fpage><lpage>2499</lpage><pub-id pub-id-type="doi">10.22207/JPAM.10.4.03</pub-id></element-citation></ref><ref id="B98-molecules-26-06057"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masoud</surname><given-names>M.S.</given-names></name>
<name><surname>Ali</surname><given-names>A.E.</given-names></name>
<name><surname>Nasr</surname><given-names>N.M.</given-names></name>
</person-group><article-title>Chemistry, classification, pharmacokinetics, clinical uses and analysis of beta lactam antibiotics: A review</article-title><source>J. Chem. Pharm. Res.</source><year>2014</year><volume>6</volume><fpage>28</fpage><lpage>58</lpage></element-citation></ref><ref id="B99-molecules-26-06057"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>D.</given-names></name>
<name><surname>Sharma</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Cephalosporins: A Review on Imperative Class of Antibiotics</article-title><source>Inventi Rapid Mol. Pharmacol.</source><year>2016</year><volume>2016</volume><fpage>17877</fpage></element-citation></ref><ref id="B100-molecules-26-06057"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ge</surname><given-names>Y.</given-names></name>
<name><surname>Maynard</surname><given-names>D.</given-names></name>
<name><surname>Rickert</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>912</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1128/AAC.00645-09</pub-id><pub-id pub-id-type="pmid">19949051</pub-id></element-citation></ref><ref id="B101-molecules-26-06057"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papp-Wallace</surname><given-names>K.M.</given-names></name>
<name><surname>Endimiani</surname><given-names>A.</given-names></name>
<name><surname>Taracila</surname><given-names>M.A.</given-names></name>
<name><surname>Bonomo</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Carbapenems: Past, present, and future</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>4943</fpage><lpage>4960</lpage><pub-id pub-id-type="doi">10.1128/AAC.00296-11</pub-id><pub-id pub-id-type="pmid">21859938</pub-id></element-citation></ref><ref id="B102-molecules-26-06057"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kropp</surname><given-names>H.</given-names></name>
<name><surname>Sundelof</surname><given-names>J.G.</given-names></name>
<name><surname>Hajdu</surname><given-names>R.</given-names></name>
<name><surname>Kahan</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I</article-title><source>Antimicrob. Agents Chemother.</source><year>1982</year><volume>22</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1128/AAC.22.1.62</pub-id><pub-id pub-id-type="pmid">7125632</pub-id></element-citation></ref><ref id="B103-molecules-26-06057"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Breilh</surname><given-names>D.</given-names></name>
<name><surname>Texier-Maugein</surname><given-names>J.</given-names></name>
<name><surname>Allaouchiche</surname><given-names>B.</given-names></name>
<name><surname>Saux</surname><given-names>M.-C.</given-names></name>
<name><surname>Boselli</surname><given-names>E.</given-names></name>
</person-group><article-title>Carbapenems</article-title><source>J. Chemother.</source><year>2013</year><volume>25</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1179/1973947812Y.0000000032</pub-id><pub-id pub-id-type="pmid">23433439</pub-id></element-citation></ref><ref id="B104-molecules-26-06057"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukasawa</surname><given-names>M.</given-names></name>
<name><surname>Sumita</surname><given-names>Y.</given-names></name>
<name><surname>Harabe</surname><given-names>E.T.</given-names></name>
<name><surname>Tanio</surname><given-names>T.</given-names></name>
<name><surname>Nouda</surname><given-names>H.</given-names></name>
<name><surname>Kohzuki</surname><given-names>T.</given-names></name>
<name><surname>Okuda</surname><given-names>T.</given-names></name>
<name><surname>Matsumura</surname><given-names>H.</given-names></name>
<name><surname>Sunagawa</surname><given-names>M.</given-names></name>
</person-group><article-title>Stability of meropenem and effect of 1&#x003b2;-methyl substitution on its stability in the presence of renal dehydropeptidase I</article-title><source>Antimicrob. Agents Chemother.</source><year>1992</year><volume>36</volume><fpage>1577</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1128/AAC.36.7.1577</pub-id><?supplied-pmid 1510457?><pub-id pub-id-type="pmid">1510457</pub-id></element-citation></ref><ref id="B105-molecules-26-06057"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bouffard</surname><given-names>F.A.</given-names></name>
<name><surname>Johnston</surname><given-names>D.B.R.</given-names></name>
<name><surname>Christensen</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Thienamycin total synthesis. 1. Synthesis of azetidinone precursors of (&#x000b1;)-thienamycin and its stereoisomers</article-title><source>J. Org. Chem.</source><year>1980</year><volume>45</volume><fpage>1130</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1021/jo01294a042</pub-id></element-citation></ref><ref id="B106-molecules-26-06057"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmitt</surname><given-names>S.M.</given-names></name>
<name><surname>Johnston</surname><given-names>D.B.R.</given-names></name>
<name><surname>Christensen</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Thienamycin total synthesis. 2. Model studies-synthesis of a simple 2-(alkylthio)carbapen-2-em</article-title><source>J. Org. Chem.</source><year>1980</year><volume>45</volume><fpage>1135</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1021/jo01294a043</pub-id></element-citation></ref><ref id="B107-molecules-26-06057"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmitt</surname><given-names>S.M.</given-names></name>
<name><surname>Johnston</surname><given-names>D.B.R.</given-names></name>
<name><surname>Christensen</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Thienamycin total synthesis. 3. Total synthesis of (&#x000b1;)-thienamycin and (&#x000b1;)-8-epithienamycin</article-title><source>J. Org. Chem.</source><year>1980</year><volume>45</volume><fpage>1142</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1021/jo01294a044</pub-id></element-citation></ref><ref id="B108-molecules-26-06057"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kametani</surname><given-names>T.</given-names></name>
<name><surname>Huang</surname><given-names>S.-P.</given-names></name>
<name><surname>Yokohama</surname><given-names>S.</given-names></name>
<name><surname>Suzuki</surname><given-names>Y.</given-names></name>
<name><surname>Ihara</surname><given-names>M.</given-names></name>
</person-group><article-title>Studies on the syntheses of heterocyclic compounds. 800. A formal total synthesis of (&#x000b1;)-thienamycin and a (&#x000b1;)-decysteaminylthienamycin derivative</article-title><source>J. Am. Chem. Soc.</source><year>1980</year><volume>102</volume><fpage>2060</fpage><lpage>2065</lpage><pub-id pub-id-type="doi">10.1021/ja00526a048</pub-id></element-citation></ref><ref id="B109-molecules-26-06057"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berks</surname><given-names>A.H.</given-names></name>
</person-group><article-title>Preparations of two pivotal intermediates for the synthesis of 1-&#x003b2;-methyl carbapenem antibiotics</article-title><source>Tetrahedron</source><year>1996</year><volume>52</volume><fpage>331</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/0040-4020(95)00842-X</pub-id></element-citation></ref><ref id="B110-molecules-26-06057"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Gamal</surname><given-names>M.I.</given-names></name>
<name><surname>Brahim</surname><given-names>I.</given-names></name>
<name><surname>Hisham</surname><given-names>N.</given-names></name>
<name><surname>Aladdin</surname><given-names>R.</given-names></name>
<name><surname>Mohammed</surname><given-names>H.</given-names></name>
<name><surname>Bahaaeldin</surname><given-names>A.</given-names></name>
</person-group><article-title>Recent updates of carbapenem antibiotics</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>131</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.03.022</pub-id><pub-id pub-id-type="pmid">28324783</pub-id></element-citation></ref><ref id="B111-molecules-26-06057"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cotroneo</surname><given-names>N.</given-names></name>
<name><surname>Rubio</surname><given-names>A.</given-names></name>
<name><surname>Critchley</surname><given-names>I.A.</given-names></name>
<name><surname>Pillar</surname><given-names>C.</given-names></name>
<name><surname>Pucci</surname><given-names>M.J.</given-names></name>
</person-group><article-title>In vitro and in vivo characterization of tebipenem, an oral carbapenem</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><elocation-id>e02240-19</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.02240-19</pub-id><pub-id pub-id-type="pmid">32423950</pub-id></element-citation></ref><ref id="B112-molecules-26-06057"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Synthesis of Faropenem</article-title><source>Zhongguo Yiyao Gongye Zazhi</source><year>2001</year><volume>32</volume><fpage>339</fpage><lpage>341</lpage></element-citation></ref><ref id="B113-molecules-26-06057"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Volkmann</surname><given-names>R.A.</given-names></name>
<name><surname>Kelbaugh</surname><given-names>P.R.</given-names></name>
<name><surname>Nason</surname><given-names>D.M.</given-names></name>
<name><surname>Jasys</surname><given-names>V.J.</given-names></name>
</person-group><article-title>2-Thioalkyl penems: An efficient synthesis of sulopenem, a (5R,6S)-6-(1(R)-hydroxyethyl)-2-[(cis-1-oxo-3-thiolanyl)thio]-2-penem antibacterial</article-title><source>J. Org. Chem.</source><year>1992</year><volume>57</volume><fpage>4352</fpage><lpage>4361</lpage><pub-id pub-id-type="doi">10.1021/jo00042a010</pub-id></element-citation></ref><ref id="B114-molecules-26-06057"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woodcock</surname><given-names>J.M.</given-names></name>
<name><surname>Andrews</surname><given-names>J.M.</given-names></name>
<name><surname>Brenwald</surname><given-names>N.P.</given-names></name>
<name><surname>Ashby</surname><given-names>J.P.</given-names></name>
<name><surname>Wise</surname><given-names>R.</given-names></name>
</person-group><article-title>The in-vitro activity of faropenem, a novel oral penem</article-title><source>J. Antimicrob. Chemother.</source><year>1997</year><volume>39</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1093/jac/39.1.35</pub-id></element-citation></ref><ref id="B115-molecules-26-06057"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schurek</surname><given-names>K.N.</given-names></name>
<name><surname>Wiebe</surname><given-names>R.</given-names></name>
<name><surname>Karlowsky</surname><given-names>J.A.</given-names></name>
<name><surname>Rubinstein</surname><given-names>E.</given-names></name>
<name><surname>Hoban</surname><given-names>D.J.</given-names></name>
<name><surname>Zhanel</surname><given-names>G.G.</given-names></name>
</person-group><article-title>Faropenem: Review of a new oral penem</article-title><source>Expert Rev. Anti-Infect. Ther.</source><year>2007</year><volume>5</volume><fpage>185</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1586/14787210.5.2.185</pub-id><pub-id pub-id-type="pmid">17402834</pub-id></element-citation></ref><ref id="B116-molecules-26-06057"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Imada</surname><given-names>A.</given-names></name>
<name><surname>Kitano</surname><given-names>K.</given-names></name>
<name><surname>Kintaka</surname><given-names>K.</given-names></name>
<name><surname>Muroi</surname><given-names>M.</given-names></name>
<name><surname>Asai</surname><given-names>M.</given-names></name>
</person-group><article-title>Sulfazecin and isosulfazecin, novel &#x003b2;-lactam antibiotics of bacterial origin</article-title><source>Nature</source><year>1981</year><volume>289</volume><fpage>590</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1038/289590a0</pub-id><pub-id pub-id-type="pmid">7007891</pub-id></element-citation></ref><ref id="B117-molecules-26-06057"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sykes</surname><given-names>R.B.</given-names></name>
<name><surname>Bonner</surname><given-names>D.P.</given-names></name>
<name><surname>Bush</surname><given-names>K.</given-names></name>
<name><surname>Georgopapadakou</surname><given-names>N.H.</given-names></name>
<name><surname>Wells</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Monobactams-monocyclic &#x003b2;-lactam antibiotics produced by bacteria</article-title><source>J. Antimicrob. Chemother.</source><year>1981</year><volume>8</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1093/jac/8.suppl_E.1</pub-id></element-citation></ref><ref id="B118-molecules-26-06057"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramsey</surname><given-names>C.</given-names></name>
<name><surname>MacGowan</surname><given-names>A.P.</given-names></name>
</person-group><article-title>A review of the pharmacokinetics and pharmacodynamics of aztreonam</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>2704</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw231</pub-id><?supplied-pmid 27334663?><pub-id pub-id-type="pmid">27334663</pub-id></element-citation></ref><ref id="B119-molecules-26-06057"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jalde</surname><given-names>S.S.</given-names></name>
<name><surname>Choi</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Recent advances in the development of &#x003b2;-lactamase inhibitors</article-title><source>J. Microbiol.</source><year>2020</year><volume>58</volume><fpage>633</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1007/s12275-020-0285-z</pub-id><?supplied-pmid 32720096?><pub-id pub-id-type="pmid">32720096</pub-id></element-citation></ref><ref id="B120-molecules-26-06057"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yahav</surname><given-names>D.</given-names></name>
<name><surname>Giske</surname><given-names>C.G.</given-names></name>
<name><surname>Graematniece</surname><given-names>A.</given-names></name>
<name><surname>Abodakpi</surname><given-names>H.</given-names></name>
<name><surname>Tam</surname><given-names>V.H.</given-names></name>
<name><surname>Leibovici</surname><given-names>L.</given-names></name>
</person-group><article-title>New &#x003b2;-Lactam-&#x003b2;-Lactamase Inhibitor Combinations</article-title><source>Clin. Microbiol. Rev.</source><year>2021</year><volume>34</volume><elocation-id>e00115</elocation-id><pub-id pub-id-type="doi">10.1128/CMR.00021-21</pub-id><?supplied-pmid 33504504?><pub-id pub-id-type="pmid">33239310</pub-id></element-citation></ref><ref id="B121-molecules-26-06057"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>A.G.</given-names></name>
<name><surname>Butterworth</surname><given-names>D.</given-names></name>
<name><surname>Cole</surname><given-names>M.</given-names></name>
<name><surname>Hanscomb</surname><given-names>G.</given-names></name>
<name><surname>Hood</surname><given-names>J.D.</given-names></name>
<name><surname>Reading</surname><given-names>C.</given-names></name>
<name><surname>Rolinson</surname><given-names>G.N.</given-names></name>
</person-group><article-title>Naturally occurring &#x003b2;-lactamase inhibitors with antibacterial activity</article-title><source>J. Antibiot.</source><year>1976</year><volume>29</volume><fpage>668</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.29.668</pub-id></element-citation></ref><ref id="B122-molecules-26-06057"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howarth</surname><given-names>T.T.</given-names></name>
<name><surname>Brown</surname><given-names>A.G.</given-names></name>
<name><surname>King</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Clavulanic acid, a novel &#x003b2;-lactam isolated from Streptomyces clavuligerus; X-ray crystal structure analysis</article-title><source>J. Chem. Soc. Chem. Commun.</source><year>1976</year><fpage>266</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1039/C3976000266B</pub-id></element-citation></ref><ref id="B123-molecules-26-06057"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buynak</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Understanding the longevity of the &#x003b2;-lactam antibiotics and of antibiotic/&#x003b2;-lactamase inhibitor combinations</article-title><source>Biochem. Pharmacol.</source><year>2006</year><volume>71</volume><fpage>930</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2005.11.012</pub-id><pub-id pub-id-type="pmid">16359643</pub-id></element-citation></ref><ref id="B124-molecules-26-06057"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harada</surname><given-names>S.</given-names></name>
<name><surname>Tsubotani</surname><given-names>S.</given-names></name>
<name><surname>Hida</surname><given-names>T.</given-names></name>
<name><surname>Ono</surname><given-names>H.</given-names></name>
<name><surname>Okazaki</surname><given-names>H.</given-names></name>
</person-group><article-title>Structure of lactivicin, an antibiotic having a new nucleus and similar biological activities to &#x003b2;-lactam antibiotics</article-title><source>Tetrahedron Lett.</source><year>1986</year><volume>27</volume><fpage>6229</fpage><lpage>6232</lpage><pub-id pub-id-type="doi">10.1016/S0040-4039(00)85439-8</pub-id></element-citation></ref><ref id="B125-molecules-26-06057"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nozaki</surname><given-names>Y.</given-names></name>
<name><surname>Katayama</surname><given-names>N.</given-names></name>
<name><surname>Ono</surname><given-names>H.</given-names></name>
<name><surname>Tsubotani</surname><given-names>S.</given-names></name>
<name><surname>Harada</surname><given-names>S.</given-names></name>
<name><surname>Okazaki</surname><given-names>H.</given-names></name>
<name><surname>Nakao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Binding of a non-&#x003b2;-lactam antibiotic to penicillin-binding proteins</article-title><source>Nature</source><year>1987</year><volume>325</volume><fpage>179</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/325179a0</pub-id><pub-id pub-id-type="pmid">3543695</pub-id></element-citation></ref><ref id="B126-molecules-26-06057"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holzgrabe</surname><given-names>U.</given-names></name>
</person-group><article-title>Lactivicin&#x02014;An antibiotic against penicillin-resistant pneumococci</article-title><source>Pharm. Unserer Zeit</source><year>2007</year><volume>36</volume><fpage>421</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/pauz.200790103</pub-id><pub-id pub-id-type="pmid">17957683</pub-id></element-citation></ref><ref id="B127-molecules-26-06057"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vazquez</surname><given-names>J.A.</given-names></name>
<name><surname>Gonzalez Patzan</surname><given-names>L.D.</given-names></name>
<name><surname>Stricklin</surname><given-names>D.</given-names></name>
<name><surname>Duttaroy</surname><given-names>D.D.</given-names></name>
<name><surname>Kreidly</surname><given-names>Z.</given-names></name>
<name><surname>Lipka</surname><given-names>J.</given-names></name>
<name><surname>Sable</surname><given-names>C.</given-names></name>
</person-group><article-title>Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: Results of a prospective, investigator-blinded, randomized study</article-title><source>Curr. Med. Res. Opin.</source><year>2012</year><volume>28</volume><fpage>1921</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1185/03007995.2012.748653</pub-id><pub-id pub-id-type="pmid">23145859</pub-id></element-citation></ref><ref id="B128-molecules-26-06057"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vazquez-Ucha</surname><given-names>J.C.</given-names></name>
<name><surname>Rodriguez</surname><given-names>D.</given-names></name>
<name><surname>Lasarte-Monterrubio</surname><given-names>C.</given-names></name>
<name><surname>Lence</surname><given-names>E.</given-names></name>
<name><surname>Arca-Suarez</surname><given-names>J.</given-names></name>
<name><surname>Maneiro</surname><given-names>M.</given-names></name>
<name><surname>Gato</surname><given-names>E.</given-names></name>
<name><surname>Perez</surname><given-names>A.</given-names></name>
<name><surname>Martinez-Guitian</surname><given-names>M.</given-names></name>
<name><surname>Juan</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to &#x003b2;-Lactam Antibiotics</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><fpage>6310</fpage><lpage>6328</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00369</pub-id><pub-id pub-id-type="pmid">33913328</pub-id></element-citation></ref><ref id="B129-molecules-26-06057"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhillon</surname><given-names>S.</given-names></name>
</person-group><article-title>Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections</article-title><source>Drugs</source><year>2018</year><volume>78</volume><fpage>1259</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1007/s40265-018-0966-7</pub-id><pub-id pub-id-type="pmid">30128699</pub-id></element-citation></ref><ref id="B130-molecules-26-06057"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morandi</surname><given-names>S.</given-names></name>
<name><surname>Morandi</surname><given-names>F.</given-names></name>
<name><surname>Caselli</surname><given-names>E.</given-names></name>
<name><surname>Shoichet</surname><given-names>B.K.</given-names></name>
<name><surname>Prati</surname><given-names>F.</given-names></name>
</person-group><article-title>Structure-based optimization of cephalothin-analogue boronic acids as &#x003b2;-lactamase inhibitors</article-title><source>Bioorg. Med. Chem.</source><year>2008</year><volume>16</volume><fpage>1195</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2007.10.075</pub-id><pub-id pub-id-type="pmid">17997318</pub-id></element-citation></ref><ref id="B131-molecules-26-06057"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barriere</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Clinical, economic and societal impact of antibiotic resistance</article-title><source>Expert Opin. Pharmacother.</source><year>2015</year><volume>16</volume><fpage>151</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1517/14656566.2015.983077</pub-id><pub-id pub-id-type="pmid">25483564</pub-id></element-citation></ref><ref id="B132-molecules-26-06057"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>R.R.</given-names></name>
<name><surname>Hota</surname><given-names>B.</given-names></name>
<name><surname>Ahmad</surname><given-names>I.</given-names></name>
<name><surname>Scott</surname><given-names>R.D.</given-names><suffix>2nd</suffix></name>
<name><surname>Foster</surname><given-names>S.D.</given-names></name>
<name><surname>Abbasi</surname><given-names>F.</given-names></name>
<name><surname>Schabowski</surname><given-names>S.</given-names></name>
<name><surname>Kampe</surname><given-names>L.M.</given-names></name>
<name><surname>Ciavarella</surname><given-names>G.G.</given-names></name>
<name><surname>Supino</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship</article-title><source>Clin. Infect. Dis.</source><year>2009</year><volume>49</volume><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1086/605630</pub-id><pub-id pub-id-type="pmid">19739972</pub-id></element-citation></ref><ref id="B133-molecules-26-06057"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boucher</surname><given-names>H.W.</given-names></name>
<name><surname>Talbot</surname><given-names>G.H.</given-names></name>
<name><surname>Benjamin</surname><given-names>D.K.</given-names><suffix>Jr.</suffix></name>
<name><surname>Bradley</surname><given-names>J.</given-names></name>
<name><surname>Guidos</surname><given-names>R.J.</given-names></name>
<name><surname>Jones</surname><given-names>R.N.</given-names></name>
<name><surname>Murray</surname><given-names>B.E.</given-names></name>
<name><surname>Bonomo</surname><given-names>R.A.</given-names></name>
<name><surname>Gilbert</surname><given-names>D.</given-names></name>
</person-group><article-title>10 &#x000d7; &#x02032;20 Progress&#x02014;Development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America</article-title><source>Clin. Infect. Dis.</source><year>2013</year><volume>56</volume><fpage>1685</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1093/cid/cit152</pub-id><pub-id pub-id-type="pmid">23599308</pub-id></element-citation></ref><ref id="B134-molecules-26-06057"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>P.</given-names></name>
<name><surname>Martens</surname><given-names>E.</given-names></name>
</person-group><article-title>Antibiotics in late clinical development</article-title><source>Biochem. Pharmacol.</source><year>2017</year><volume>133</volume><fpage>152</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.09.025</pub-id><pub-id pub-id-type="pmid">27687641</pub-id></element-citation></ref><ref id="B135-molecules-26-06057"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Remy</surname><given-names>V.</given-names></name>
<name><surname>Largeron</surname><given-names>N.</given-names></name>
<name><surname>Quilici</surname><given-names>S.</given-names></name>
<name><surname>Carroll</surname><given-names>S.</given-names></name>
</person-group><article-title>The economic value of vaccination: Why prevention is wealth</article-title><source>J. Mark. Access Health Policy</source><year>2015</year><volume>3</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.3402/jmahp.v3.29284</pub-id></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Schemes and Table</title><fig position="float" id="molecules-26-06057-f001"><label>Figure 1</label><caption><p>The commonly shown structure for arsphenamine (salvarsan) is <bold>1a</bold>. Arsphenamine is now known to be a mixture of compounds with the formula <bold>1b</bold>, in which n varies from 1 to 7. The predominant values are n = 1 and n = 3. Neosalvarsan (<bold>2a</bold>) was designed to increase the solubility [<xref rid="B18-molecules-26-06057" ref-type="bibr">18</xref>]. Oxphenarsine <bold>3</bold> is the expected active metabolite of arspehamine [<xref rid="B24-molecules-26-06057" ref-type="bibr">24</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g001" position="float"/></fig><fig position="float" id="molecules-26-06057-f002"><label>Figure 2</label><caption><p>Prontosil (<bold>4</bold>), sulfonamide (4-aminobenzenesulfonamiode, <bold>5</bold>) and 4-sulfapyridine (<bold>6</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g002" position="float"/></fig><fig position="float" id="molecules-26-06057-sch001"><object-id pub-id-type="pii">molecules-26-06057-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Biosynthesis of tetrahydrofolate (<bold>10</bold>) from 7,8-dihydropteridinepyrophosphate (<bold>7</bold>) and 4-aminobenzoic acid (<bold>8</bold>) via 7,8-dihydropteroate (<bold>9</bold>) and dihydrofolate (<bold>11</bold>) [<xref rid="B36-molecules-26-06057" ref-type="bibr">36</xref>]. Dihydropteroate synthase (E1), dihydrofolate synthase (E2) and dihydrofoate reductase (E3) [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch001" position="float"/></fig><fig position="float" id="molecules-26-06057-f003"><label>Figure 3</label><caption><p>Clinically used sulfonamides for treatment of infectious diseases: sulfonilamide (<bold>5</bold>), sulfapyridine (<bold>6)</bold>, sulfathiazole (<bold>12)</bold>, sulfamehoxazole (<bold>13)</bold>, sulfamerazine (<bold>14)</bold>, sulfadiazine (<bold>15)</bold>, sulfabromomethazine (<bold>16)</bold>, sulfamethoxypyridazine (<bold>17)</bold>, sulfachloropyridazine (<bold>18)</bold>, sulfametazine (<bold>19)</bold>, sulfaethoxypyridazine (<bold>20)</bold> and sulfadimethoxine (<bold>21)</bold> [<xref rid="B36-molecules-26-06057" ref-type="bibr">36</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g003" position="float"/></fig><fig position="float" id="molecules-26-06057-f004"><label>Figure 4</label><caption><p>Naturally occurring &#x003b2;-lactams backbones [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g004" position="float"/></fig><fig position="float" id="molecules-26-06057-f005"><label>Figure 5</label><caption><p>Structures of penicillins with British and American names. Penicillin-I/<italic toggle="yes">F</italic>-penicillin (<bold>22</bold>), dihydropenicillin-I (<bold>23</bold>), penicillin-II/<italic toggle="yes">G</italic>-penicillin (<bold>24</bold>), penicillin-III/<italic toggle="yes">X</italic>-penicillin (<bold>25</bold>) and K-penicillin (<bold>26</bold>). The side chain is dependent on the <italic toggle="yes">Pencillium</italic> species and broth from which the penicillin is isolated.</p></caption><graphic xlink:href="molecules-26-06057-g005" position="float"/></fig><fig position="float" id="molecules-26-06057-sch002"><object-id pub-id-type="pii">molecules-26-06057-sch002_Scheme 2</object-id><label>Scheme 2</label><caption><p>Structure elucidation of penicillin. Hydrolysis with mineral acid affords carbon dioxide, penicillamine (<bold>28</bold>) and penaldic acid (<bold>27</bold>), which is labile and spontaneously converted into penillo-aldehyde (<bold>29</bold>). Treatment with benzylamine yields aminolysis of the &#x003b2;-lactam to give the benzylammonium salt of the benzylamide <bold>30</bold>. Methanolysis affords the monomethyl ester of methyl penicilloate (<bold>31</bold>), which may be converted into methyl penaldoate and (<bold>32</bold>) and penicillamine (<bold>28</bold>). The suggested structures have been confirmed by syntheses [<xref rid="B47-molecules-26-06057" ref-type="bibr">47</xref>,<xref rid="B48-molecules-26-06057" ref-type="bibr">48</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch002" position="float"/></fig><fig position="float" id="molecules-26-06057-sch003"><object-id pub-id-type="pii">molecules-26-06057-sch003_Scheme 3</object-id><label>Scheme 3</label><caption><p>In aqueous solution pencillin is hydrolyzed (black arrows) to penicilloic acid (<bold>33</bold>), which rearranges into penillic acid (<bold>34</bold>). Catalyzed by mercury ions <bold>34</bold> is converted into penillamine (<bold>35</bold>), or catalyzed by barium sulfate (red arrows) isomerize into isopenicillic acid (<bold>36</bold>) by a retro Hetero-Michael addition [<xref rid="B47-molecules-26-06057" ref-type="bibr">47</xref>,<xref rid="B48-molecules-26-06057" ref-type="bibr">48</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch003" position="float"/></fig><fig position="float" id="molecules-26-06057-sch004"><object-id pub-id-type="pii">molecules-26-06057-sch004_Scheme 4</object-id><label>Scheme 4</label><caption><p>Resonance of penicillin and reaction with penicillin-binding peptide to acylate the penicillin-binding peptide (<bold>37</bold>) followed by hydrolysis [<xref rid="B45-molecules-26-06057" ref-type="bibr">45</xref>,<xref rid="B47-molecules-26-06057" ref-type="bibr">47</xref>,<xref rid="B48-molecules-26-06057" ref-type="bibr">48</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch004" position="float"/></fig><fig position="float" id="molecules-26-06057-sch005"><object-id pub-id-type="pii">molecules-26-06057-sch005_Scheme 5</object-id><label>Scheme 5</label><caption><p>Biosynthesis of the non-ribosomal peptide penicillin G [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>]. EnzFe: isopenicillin <italic toggle="yes">N</italic>-synthase-FeII, transferase: isopenicillin N <italic toggle="yes">N</italic>-acyltransferase [<xref rid="B54-molecules-26-06057" ref-type="bibr">54</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch005" position="float"/></fig><fig position="float" id="molecules-26-06057-f006"><label>Figure 6</label><caption><p>6-Aminopenicillanic acid (<bold>38</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g006" position="float"/></fig><fig position="float" id="molecules-26-06057-f007"><label>Figure 7</label><caption><p>Cartoon illustrating the cross binding of peptidoglycan strands in the cell walls of <italic toggle="yes">Staphyllococcus aureus</italic> [<xref rid="B52-molecules-26-06057" ref-type="bibr">52</xref>,<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>]. Pe indicates the attachment of an additional cross binding peptide by a peptide bond to <italic toggle="yes">N</italic>-acetymuramic acid. G indicates prolongation with other units of the dimer <italic toggle="yes">N</italic>-acetylglucosamine-<italic toggle="yes">N</italic>-acetylmuramic acid.</p></caption><graphic xlink:href="molecules-26-06057-g007" position="float"/></fig><fig position="float" id="molecules-26-06057-f008"><label>Figure 8</label><caption><p>Mechanism for cross binding [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>,<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>]. Pe indicates the attachment of an additional cross binding peptide by a peptide bond to <italic toggle="yes">N</italic>-acetymuramic acid. G indicates prolongation with other units of the dimer <italic toggle="yes">N</italic>-acetylglucosamine-<italic toggle="yes">N</italic>-acetylmuramic acid.</p></caption><graphic xlink:href="molecules-26-06057-g008" position="float"/></fig><fig position="float" id="molecules-26-06057-f009"><label>Figure 9</label><caption><p>Semisynthetic penicillins. Phenoxyacyl penicillins: phenoxymethyl penicillin/penicillin V (Vepicombin, <bold>39</bold>), phenoxyethyl penicillin (phenithicillin, <bold>40</bold>), Phenoxypropylpenicillin (<bold>41</bold>) [<xref rid="B63-molecules-26-06057" ref-type="bibr">63</xref>,<xref rid="B64-molecules-26-06057" ref-type="bibr">64</xref>]. Aminoacylpenicillins ampicillin (<bold>42</bold>), epicillin (<bold>43</bold>), amoxicillin (<bold>44</bold>) and cyclacillin (<bold>45</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g009" position="float"/></fig><fig position="float" id="molecules-26-06057-f010"><label>Figure 10</label><caption><p>Semisynthetic penicillins with activity toward <italic toggle="yes">Pseudomonas aeruginosa</italic> Carbenicillin (<bold>46</bold>), sulbenicillin (<bold>47</bold>), ticarcillin (<bold>48</bold>) [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>], piperacillin (<bold>49</bold>) and mezlocillin (<bold>50</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g010" position="float"/></fig><fig position="float" id="molecules-26-06057-f011"><label>Figure 11</label><caption><p>Examples of &#x003b2;-lactamase resistant penicillins, methicillin (<bold>51</bold>), nafcillin (<bold>52</bold>) and oxacillin (<bold>53</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g011" position="float"/></fig><fig position="float" id="molecules-26-06057-sch006"><object-id pub-id-type="pii">molecules-26-06057-sch006_Scheme 6</object-id><label>Scheme 6</label><caption><p>Conversion of penicillin G into the 6-methoxy derivative <bold>54</bold> [<xref rid="B82-molecules-26-06057" ref-type="bibr">82</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch006" position="float"/></fig><fig position="float" id="molecules-26-06057-f012"><label>Figure 12</label><caption><p>Temocillin (<bold>55</bold>) and formadicillin (<bold>56</bold>) [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>]. Temocillin is approved by European Medicine Agency.</p></caption><graphic xlink:href="molecules-26-06057-g012" position="float"/></fig><fig position="float" id="molecules-26-06057-f013"><label>Figure 13</label><caption><p>Ureidopenicillins: Azlocillin (<bold>51</bold>), mezlocillin (<bold>52</bold>) and piperazillin (<bold>53</bold>) [<xref rid="B38-molecules-26-06057" ref-type="bibr">38</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g013" position="float"/></fig><fig position="float" id="molecules-26-06057-f014"><label>Figure 14</label><caption><p>Prodrugs of penicillin: talampicillin (<bold>60</bold>), bacampicillin (<bold>61</bold>), pivampicillin (<bold>62</bold>) and lenampenicillin (<bold>63</bold>) [<xref rid="B42-molecules-26-06057" ref-type="bibr">42</xref>,<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g014" position="float"/></fig><fig position="float" id="molecules-26-06057-f015"><label>Figure 15</label><caption><p>Cephalosporin C (<bold>64</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g015" position="float"/></fig><fig position="float" id="molecules-26-06057-sch007"><object-id pub-id-type="pii">molecules-26-06057-sch007_Scheme 7</object-id><label>Scheme 7</label><caption><p>Pencillin cephalosporin rearrangement [<xref rid="B95-molecules-26-06057" ref-type="bibr">95</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch007" position="float"/></fig><fig position="float" id="molecules-26-06057-sch008"><object-id pub-id-type="pii">molecules-26-06057-sch008_Scheme 8</object-id><label>Scheme 8</label><caption><p>Cleavage of the 7-amide group of cephalosporins [<xref rid="B44-molecules-26-06057" ref-type="bibr">44</xref>,<xref rid="B97-molecules-26-06057" ref-type="bibr">97</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch008" position="float"/></fig><fig position="float" id="molecules-26-06057-sch009"><object-id pub-id-type="pii">molecules-26-06057-sch009_Scheme 9</object-id><label>Scheme 9</label><caption><p>Biosynthesis of cephalosporin C (<bold>64</bold>). Isomerase: isopenicillin N isomerase, ring expansion, oxidation and acetylation: deacetylcephalosporin C/deacetylcephalosporin C synthase-FeII, acetylation deacetylcephalosprin C acetyltransferase [<xref rid="B37-molecules-26-06057" ref-type="bibr">37</xref>,<xref rid="B54-molecules-26-06057" ref-type="bibr">54</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch009" position="float"/></fig><fig position="float" id="molecules-26-06057-f016"><label>Figure 16</label><caption><p>Examples of first generation cephalosporins. Cephalexin (<bold>65</bold>), cefadrine (<bold>66</bold>) and cefadroxil (<bold>67</bold>). Second generation cephalosporins cefalclor (<bold>68</bold>) and cefuroxime (<bold>69</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g016" position="float"/></fig><fig position="float" id="molecules-26-06057-f017"><label>Figure 17</label><caption><p>Third generation cephalosporins. Cefotaxime (<bold>70</bold>), ceftazidime (<bold>71</bold>), ceftriaxone (<bold>72</bold>) and ceftizoxime (<bold>73</bold>). Fourth generation cephalosporins. Cefepime (<bold>74</bold>), cefpirome (<bold>75</bold>) and cefquinome (<bold>76</bold>). Fifth generation cephalosporins: ceftobiprole (<bold>77</bold>) and ceftaroline fosamil (<bold>78</bold>) [<xref rid="B98-molecules-26-06057" ref-type="bibr">98</xref>,<xref rid="B99-molecules-26-06057" ref-type="bibr">99</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g017" position="float"/></fig><fig position="float" id="molecules-26-06057-f018"><label>Figure 18</label><caption><p>Carbapenems and 1-methylcarbapenems. Olivanic acid (<bold>79</bold>), thienamycin (<bold>80</bold>), imipenem (<bold>81</bold>), panipenem (<bold>82</bold>), biapenem (<bold>83</bold>), meropenem (<bold>84</bold>), ertapenem (<bold>85</bold>) and doripenem (<bold>86</bold>) [<xref rid="B101-molecules-26-06057" ref-type="bibr">101</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g018" position="float"/></fig><fig position="float" id="molecules-26-06057-f019"><label>Figure 19</label><caption><p>Tebipenem pivoxil (<bold>88</bold>) and sanfetrinem (<bold>89</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g019" position="float"/></fig><fig position="float" id="molecules-26-06057-f020"><label>Figure 20</label><caption><p>Faropenem (<bold>90</bold>), faropenem medoximil (<bold>91</bold>), sulopenem (<bold>92</bold>) and sulopenem etzadrozil (<bold>93</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g020" position="float"/></fig><fig position="float" id="molecules-26-06057-sch010"><object-id pub-id-type="pii">molecules-26-06057-sch010_Scheme 10</object-id><label>Scheme 10</label><caption><p>Formation of the thipenem skeleton [<xref rid="B113-molecules-26-06057" ref-type="bibr">113</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch010" position="float"/></fig><fig position="float" id="molecules-26-06057-sch011"><object-id pub-id-type="pii">molecules-26-06057-sch011_Scheme 11</object-id><label>Scheme 11</label><caption><p>Hydrolysis of sulfazecin (<bold>95</bold>).</p></caption><graphic xlink:href="molecules-26-06057-sch011" position="float"/></fig><fig position="float" id="molecules-26-06057-f021"><label>Figure 21</label><caption><p>Aztreonam (<bold>96</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g021" position="float"/></fig><fig position="float" id="molecules-26-06057-f022"><label>Figure 22</label><caption><p>&#x003b2;-Lactamase inhibitors containing a &#x003b2;-lactam residue in the skeleton: clavulanic acid (<bold>97</bold>), sulbactam (<bold>98</bold>), tazobactam (<bold>99</bold>) and enmetazobactam (<bold>100</bold>) [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g022" position="float"/></fig><fig position="float" id="molecules-26-06057-sch012"><object-id pub-id-type="pii">molecules-26-06057-sch012_Scheme 12</object-id><label>Scheme 12</label><caption><p>Irreversibel reaction between sulbactam (<bold>98</bold>) and &#x003b2;-lactamase [<xref rid="B123-molecules-26-06057" ref-type="bibr">123</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch012" position="float"/></fig><fig position="float" id="molecules-26-06057-sch013"><object-id pub-id-type="pii">molecules-26-06057-sch013_Scheme 13</object-id><label>Scheme 13</label><caption><p>Reaction of lactivicin (<bold>101</bold>) and phenoxylactivicin (<bold>102</bold>) with pencillin binding proteins [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch013" position="float"/></fig><fig position="float" id="molecules-26-06057-f023"><label>Figure 23</label><caption><p>Avibactam (<bold>103</bold>) and NXL-105 (<bold>104</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g023" position="float"/></fig><fig position="float" id="molecules-26-06057-sch014"><object-id pub-id-type="pii">molecules-26-06057-sch014_Scheme 14</object-id><label>Scheme 14</label><caption><p>Reaction of avibactam (<bold>103</bold>) with PBP. The carbamoyl-lactamase complex is more stable than the analogous complexes between lactamase inhibitors of the &#x003b2;-lactam type [<xref rid="B58-molecules-26-06057" ref-type="bibr">58</xref>].</p></caption><graphic xlink:href="molecules-26-06057-sch014" position="float"/></fig><fig position="float" id="molecules-26-06057-f024"><label>Figure 24</label><caption><p>Boronic acid &#x003b2;-lactamase inhibitors. Vaborbactam (<bold>105</bold>) and taniborbactam (<bold>106</bold>).</p></caption><graphic xlink:href="molecules-26-06057-g024" position="float"/></fig><fig position="float" id="molecules-26-06057-f025"><label>Figure 25</label><caption><p>Serine-&#x003b2;-lactamase-varbobactam complex [<xref rid="B129-molecules-26-06057" ref-type="bibr">129</xref>] and metallo-&#x003b2;-lactamase-taniborbactam complex [<xref rid="B119-molecules-26-06057" ref-type="bibr">119</xref>].</p></caption><graphic xlink:href="molecules-26-06057-g025" position="float"/></fig><table-wrap position="float" id="molecules-26-06057-t001"><object-id pub-id-type="pii">molecules-26-06057-t001_Table 1</object-id><label>Table 1</label><caption><p>New antibiotic drugs approved by FDA in the period 1983&#x02013;2012 [<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>,<xref rid="B134-molecules-26-06057" ref-type="bibr">134</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Period</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1983&#x02013;1987</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1988&#x02013;1992</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1993&#x02013;1997</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1998&#x02013;2002</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2003&#x02013;2007</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2008&#x02013;2012</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B133-molecules-26-06057" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2011&#x02013;2017</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B134-molecules-26-06057" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014&#x02013;2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-molecules-26-06057" ref-type="bibr">84</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The last two entrances are taken from different reference explaining the deviation.</p></fn></table-wrap-foot></table-wrap></sec></back></article>